≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Disorders of phosphorus metabolism and phosphatases

DOID EFO Endpoint Browser PheWeb

E4_PHOS_MET

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E83.3
  • Hospital discharge: ICD-9 — 2753
  • Cause of death: ICD-10 — E83.3
  • Cause of death: ICD-9 — 2753
  • KELA reimbursements: KELA codes — ANY
  • KELA reimbursements: ICD-10 — E83.3

3 out of 7 registries used, show all original rules.

190

4. Check minimum number of events

None

190

5. Include endpoints

None

190

6. Filter based on genotype QC (FinnGen only)

184

Control definitions (FinnGen only)

Control exclude
E4_METABOLIA

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E83
Name in latin
Perturbationes metabolismi phosphori

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 908 443 459
Only index persons 819 399 420
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.02 0.01 0.02
Median age at first event (years)
Whole population 54.06 52.80 55.17
Only index persons 54.59 53.52 55.61

-FinnGen-

Key figures

All Female Male
Number of individuals 184 96 88
Unadjusted period prevalence (%) 0.04 0.03 0.04
Median age at first event (years) 53.84 50.34 57.66

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
190
Matched controls
1900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E83.39
ICD-10 Finland
Other disorder of phosphorus metabolism
+∞
205.4
158
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
94.1
55.0
59
9
A11CC03
ATC
alfacalcidol; systemic
78.8
47.3
52
9
V03AG01
ATC
sodium cellulose phosphate; systemic
513.5
43.0
41
*
E87.6
ICD-10 Finland
Hypokalaemia
91.8
39.9
43
6
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
9.1
31.6
44
61
E83.4
ICD-10 Finland
Disorders of magnesium metabolism
+∞
28.9
27
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
13.0
28.2
29
26
E83.3
ICD-10 Finland
Disorders of phosphorus metabolism and phosphatases
+∞
27.8
26
*
E83.30
ICD-10 Finland
Acid phosphatase deficiency
+∞
26.7
25
*
E83.51
ICD-10 Finland
Hypocalcemia
149.7
25.3
26
*
A12AA04
ATC
calcium carbonate; oral
65.2
24.8
28
5
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.5
23.1
90
318
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.4
23.1
100
382
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
7.7
20.7
32
49
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
5.8
19.5
41
86
D64.9
ICD-10 Finland
Anaemia, unspecified
5.4
17.6
40
90
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
55.5
17.4
20
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.2
17.1
40
92
M05BX04
ATC
denosumab; parenteral
7.6
17.1
26
39
JN3AD
NOMESCO Finland
Abdominal CT examination
4.6
16.7
48
131
E83.50
ICD-10 Finland
Hypercalcemia
87.0
14.8
16
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.0
14.5
51
161
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
14.2
49
152
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.8
13.4
34
83
AA1AD
NOMESCO Finland
CT of head and brain
3.3
13.4
71
291
N17.9
ICD-10 Finland
Acute renal failure, unspecified
12.9
12.7
22
19
C03CA01
ATC
furosemide; systemic
3.2
12.4
64
257
R4190
NOMESCO Finland
Nutritional therapy
5.4
12.3
26
54
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.3
12.1
26
55
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.6
11.8
46
154
WZC00
NOMESCO Finland
Treatment plan or consultation
2.9
11.7
95
489
TPH07
NOMESCO Finland
Cathetrisation of artery
4.2
11.6
34
93
M05BA04
ATC
alendronic acid; oral
5.2
11.3
25
54
X59
ICD-10 Finland
Exposure to unspecified factor
3.2
11.1
57
226
ZX120
NOMESCO Finland
Intravenous
4.4
11.1
30
77
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
4.4
10.8
29
74
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.0
10.6
34
99
H02AB09
ATC
hydrocortisone; systemic
13.1
10.6
18
15
B05XA09
ATC
sodium phosphate; parenteral
+∞
10.5
10
*
2753A
ICD-9 Finland
Disorders of mineral metabolism, Disorders of phosphorus metabolism[HYPOPHOSPHATHAEMIA FAMILIARIS]
+∞
10.5
10
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.9
10.3
34
101
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
10.2
108
624
SBB10
NOMESCO Finland
Dental impressions
3.7
10.0
35
108
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.9
10.0
59
252
N06AX11
ATC
mirtazapine; oral
2.7
9.9
83
425
R56.8
ICD-10 Finland
Other and unspecified convulsions
5.1
9.8
22
48
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.4
9.8
40
137
R50.9
ICD-10 Finland
Fever, unspecified
3.2
9.8
48
184
321
Kela drug reimbursment
Paricalcitol and cinacalcet
58.0
9.8
11
*
WX002
NOMESCO Finland
Sedation and analgesia
3.1
9.7
49
191
A02BC02
ATC
pantoprazole; systemic
2.9
9.6
143
968
WX408
NOMESCO Finland
General anesthesy, balanced
2.8
9.6
65
298
E86
ICD-10 Finland
Volume depletion
31.8
9.5
12
*
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
5.2
9.3
20
42
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
16.7
9.2
14
9
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
8.8
82
437
L04AX01
ATC
azathioprine; systemic
7.6
8.8
20
29
H02AB06
ATC
prednisolone; systemic
2.5
8.8
101
594
H05BX01
ATC
cinacalcet; oral
52.5
8.8
10
*
E21.2
ICD-10 Finland
Other hyperparathyroidism
52.5
8.8
10
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
17.3
8.7
13
8
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
11.5
8.5
15
14
E83.9
ICD-10 Finland
Disorder of mineral metabolism, unspecified
+∞
8.4
8
*
R4110
NOMESCO Finland
Physiotherapy
2.6
8.4
70
353
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
8.3
54
240
KA1AE
NOMESCO Finland
Kidney ultrasound examination
9.6
8.2
16
18
L04AD02
ATC
tacrolimus; systemic
18.2
8.2
12
7
E55.9
ICD-10 Finland
Vitamin D deficiency, unspecified
35.0
8.2
10
*
SBB20
NOMESCO Finland
Tooth X-ray examination in conjunction with visit to dentist
23.2
8.1
11
5
127
Kela drug reimbursment
Transplant complication
13.8
8.0
13
10
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
6.4
7.9
20
34
UJF30
NOMESCO Finland
Ileoscopy through colon
3.5
7.9
29
92
K04.5
ICD-10 Finland
Chronic apical periodontitis
2.5
7.9
65
324
UJF32
NOMESCO Finland
Coloscopy
2.6
7.9
60
288
A28
ICPC
Limited function/disability NOS
3.0
7.8
39
150
SPA00
NOMESCO Finland
Changing form of teeth in prepation for prosthodontic work
7.2
7.8
18
27
N02AX02
ATC
tramadol; systemic, rectal
2.4
7.8
91
531
R11
ICD-10 Finland
Nausea and vomiting
3.5
7.8
29
93
M81.9
ICD-10 Finland
Osteoporosis, unspecified
7.7
7.7
17
24
K70.0
ICD-10 Finland
Alcoholic fatty liver
83.2
7.5
8
*
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
6.7
7.4
18
29
A03FA01
ATC
metoclopramide; systemic, rectal
2.6
7.4
52
240
A12AA06
ATC
calcium lactate gluconate; oral
+∞
7.3
7
*
E83.8
ICD-10 Finland
Other disorders of mineral metabolism
+∞
7.3
7
*
Z94.0
ICD-10 Finland
Kidney transplant status
21.0
7.2
10
5
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.0
7.1
35
133
Z2446
NOMESCO Finland
Social worker
3.5
7.0
26
83
N18.8
ICD-10 Finland
Other chronic renal failure
14.5
7.0
11
8
XF600
NOMESCO Finland
Bloodpressure measurement
3.9
7.0
21
58
WX892
NOMESCO Finland
Monitored bed care
3.9
7.0
21
58
M13.9
ICD-10 Finland
Arthritis, unspecified
3.8
6.9
22
63
A04
ICPC
Weakness/tiredness general
2.9
6.9
37
148
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.9
6.9
37
148
F10.31
ICD-10 Finland
Withdrawal symptoms caused by alcohol with seizures
41.6
6.8
8
*
B05DB
ATC
Hypertonic solutions
41.6
6.8
8
*
V03AE01
ATC
polystyrene sulfonate; oral
41.6
6.8
8
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
41.6
6.8
8
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.3
6.8
18
45
EBA15
NOMESCO Finland
Extraction of multiple teeth
6.3
6.8
17
29
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
23.5
6.7
9
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.2
6.7
29
102
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.2
6.6
94
586
ZXE00
NOMESCO Finland
One hour or less
2.2
6.6
84
501
C07AB02
ATC
metoprolol; systemic
2.8
6.6
38
158
205
Kela drug reimbursment
Chronic hypertension
2.5
6.5
46
212
Z3226
NOMESCO Finland
Physiotherapist
2.5
6.5
46
212
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
6.4
6.5
16
27
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.1
6.4
28
99
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
9.8
6.4
12
13
TK800
NOMESCO Finland
Hemodialysis
11.6
6.4
11
10
WW500
NOMESCO Finland
Blood transfusion
5.4
6.4
18
36
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.6
6.4
22
67
137
Kela drug reimbursment
Uraemia requiring dialysis
18.8
6.3
9
5
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.2
6.3
26
89
A11CC02
ATC
dihydrotachysterol; oral
+∞
6.3
6
*
E21.1
ICD-10 Finland
Secondary hyperparathyroidism, not elsewhere classified
+∞
6.3
6
*
26510
ICD-8 Finland
Vitamin D deficiency, Rickets, late effect
+∞
6.3
6
*
E55.0
ICD-10 Finland
Rickets, active
+∞
6.3
6
*
EB1JA
NOMESCO Finland
Double panorama tomography of teeth and jaws or similar X-ray examination
27.7
6.3
8
*
B05DA
ATC
Isotonic solutions
27.7
6.3
8
*
N30.0
ICD-10 Finland
Acute cystitis
2.7
6.3
36
149
Z31.5
ICD-10 Finland
Genetic counselling
3.6
6.2
21
63
N05BA04
ATC
oxazepam; oral
2.3
6.2
55
281
M54.5
ICD-10 Finland
Low back pain
2.2
6.1
78
462
R53
ICD-10 Finland
Malaise and fatigue
2.3
6.1
58
305
N02AA05
ATC
oxycodone; systemic
2.6
6.0
39
171
N05CD07
ATC
temazepam; oral
3.4
6.0
23
75

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.7e+00
2.8e+00
4.0e+00
1.0e+50
5.3e+00
3.6e+00
2.8e+00
cases:14.12%
controls:2.94%
cases:17.51%
controls:1.25%
cases:20.34%
controls:0.45%
cases:18.08%
controls:0.00%
cases:40.91%
controls:0.34%
cases:34.59%
controls:1.36%
cases:30.65%
controls:2.68%
25
52
152
1715
31
22
146
1745
36
8
141
1759
32
0
145
1767
72
6
104
1755
55
23
104
1669
38
39
86
1417
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.9e+00
2.7e+00
4.1e+00
1.0e+50
5.1e+00
3.2e+00
2.1e+00
cases:15.82%
controls:2.83%
cases:15.82%
controls:1.19%
cases:14.12%
controls:0.28%
cases:18.08%
controls:0.00%
cases:32.39%
controls:0.28%
cases:22.01%
controls:1.12%
cases:18.55%
controls:2.82%
28
50
149
1717
28
21
149
1746
25
5
152
1762
32
0
145
1767
57
5
119
1756
35
19
124
1673
23
41
101
1415
Nephrology
39 [38004479]
2.3e+00
2.5e+00
3.1e+00
—
3.1e+00
3.0e+00
2.4e+00
cases:5.65%
controls:0.62%
cases:6.21%
controls:0.57%
cases:6.21%
controls:0.28%
—
—
cases:6.25%
controls:0.28%
cases:7.55%
controls:0.41%
cases:5.65%
controls:0.55%
10
11
167
1756
11
10
166
1757
11
5
166
1762
—
11
5
165
1756
12
7
147
1685
7
8
117
1448
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.7e+00
2.6e+00
2.3e+00
1.0e+50
3.5e+00
3.0e+00
1.9e+00
cases:10.73%
controls:2.09%
cases:8.47%
controls:0.68%
cases:4.52%
controls:0.45%
cases:3.39%
controls:0.00%
cases:8.52%
controls:0.28%
cases:12.58%
controls:0.71%
cases:11.29%
controls:1.79%
19
37
158
1730
15
12
162
1755
8
8
169
1759
6
0
171
1767
15
5
161
1756
20
12
139
1680
14
26
110
1430
pH of Serum or Plasma
2753-2 [3018418]
1.2e+00
2.1e+00
3.0e+00
1.0e+50
4.0e+00
2.5e+00
1.8e+00
cases:17.51%
controls:6.11%
cases:19.21%
controls:2.94%
cases:16.95%
controls:1.02%
cases:7.91%
controls:0.00%
cases:21.59%
controls:0.51%
cases:24.53%
controls:2.66%
cases:31.45%
controls:6.94%
31
108
146
1659
34
52
143
1715
30
18
147
1749
14
0
163
1767
38
9
138
1752
39
45
120
1647
39
101
85
1355
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.2e+00
2.0e+00
3.1e+00
—
4.0e+00
2.3e+00
1.7e+00
cases:26.55%
controls:9.90%
cases:25.99%
controls:4.70%
cases:23.73%
controls:1.41%
—
—
cases:34.09%
controls:0.91%
cases:30.82%
controls:4.26%
cases:39.52%
controls:10.92%
47
175
130
1592
46
83
131
1684
42
25
135
1742
—
60
16
116
1745
49
72
110
1620
49
159
75
1297
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.1e+00
1.9e+00
3.0e+00
—
3.8e+00
2.4e+00
1.7e+00
cases:26.55%
controls:10.81%
cases:29.38%
controls:5.66%
cases:24.29%
controls:1.53%
—
—
cases:35.80%
controls:1.19%
cases:34.59%
controls:4.79%
cases:42.74%
controls:11.95%
47
191
130
1576
52
100
125
1667
43
27
134
1740
—
63
21
113
1740
55
81
104
1611
53
174
71
1282
Internal Medicine
11 [38004456]
1.2e+00
1.9e+00
3.0e+00
—
3.4e+00
2.3e+00
1.8e+00
cases:40.11%
controls:16.30%
cases:24.29%
controls:4.75%
cases:15.25%
controls:0.91%
—
—
cases:22.73%
controls:0.97%
cases:36.48%
controls:5.20%
cases:48.39%
controls:13.19%
71
288
106
1479
43
84
134
1683
27
16
150
1751
—
40
17
136
1744
58
88
101
1604
60
192
64
1264
Bacteria identified in Blood by Culture
600-7 [3023368]
1.1e+00
2.0e+00
3.0e+00
1.0e+50
3.7e+00
2.0e+00
1.3e+00
cases:14.69%
controls:5.21%
cases:12.43%
controls:1.87%
cases:7.34%
controls:0.40%
cases:8.47%
controls:0.00%
cases:10.23%
controls:0.28%
cases:11.32%
controls:1.77%
cases:17.74%
controls:5.70%
26
92
151
1675
22
33
155
1734
13
7
164
1760
15
0
162
1767
18
5
158
1756
18
30
141
1662
22
83
102
1373
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.2e+00
1.8e+00
2.7e+00
—
3.8e+00
2.1e+00
1.1e+00
cases:25.42%
controls:9.56%
cases:23.16%
controls:4.87%
cases:12.99%
controls:1.02%
—
—
cases:19.89%
controls:0.57%
cases:25.79%
controls:4.26%
cases:28.23%
controls:11.47%
45
169
132
1598
41
86
136
1681
23
18
154
1749
—
35
10
141
1751
41
72
118
1620
35
167
89
1289
Emergency Room and Inpatient Visit
ERIP [262]
1.2e+00
1.9e+00
2.6e+00
—
3.7e+00
1.7e+00
1.0e+00
cases:16.38%
controls:5.55%
cases:15.25%
controls:2.72%
cases:7.91%
controls:0.62%
—
—
cases:12.50%
controls:0.34%
cases:14.47%
controls:3.07%
cases:19.35%
controls:8.10%
29
98
148
1669
27
48
150
1719
14
11
163
1756
—
22
6
154
1755
23
52
136
1640
24
118
100
1338
potassium chloride; oral
A12BA01 [21600877]
2.1e+00
2.4e+00
—
—
3.1e+00
2.7e+00
1.7e+00
cases:7.34%
controls:0.96%
cases:7.34%
controls:0.74%
—
—
—
—
cases:6.82%
controls:0.34%
cases:10.06%
controls:0.71%
cases:8.06%
controls:1.58%
13
17
164
1750
13
13
164
1754
—
—
12
6
164
1755
16
12
143
1680
10
23
114
1433
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.9e-01
9.7e-01
2.3e+00
4.8e+00
2.7e+00
1.0e+00
5.8e-01
cases:44.63%
controls:33.16%
cases:39.55%
controls:19.81%
cases:27.12%
controls:3.62%
cases:29.94%
controls:0.34%
cases:37.50%
controls:3.86%
cases:40.25%
controls:19.62%
cases:53.23%
controls:39.01%
79
586
98
1181
70
350
107
1417
48
64
129
1703
53
6
124
1761
66
68
110
1693
64
332
95
1360
66
568
58
888
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
6.8e-01
1.6e+00
2.9e+00
1.0e+50
4.3e+00
1.8e+00
1.2e+00
cases:15.25%
controls:8.32%
cases:17.51%
controls:4.07%
cases:10.73%
controls:0.68%
cases:2.82%
controls:0.00%
cases:20.45%
controls:0.34%
cases:23.90%
controls:5.14%
cases:35.48%
controls:14.22%
27
147
150
1620
31
72
146
1695
19
12
158
1755
5
0
172
1767
36
6
140
1755
38
87
121
1605
44
207
80
1249
Endocrinology
46 [38004485]
1.3e+00
1.7e+00
—
1.0e+50
3.1e+00
2.8e+00
2.6e+00
cases:11.30%
controls:3.23%
cases:9.04%
controls:1.75%
—
—
cases:13.56%
controls:0.00%
cases:7.39%
controls:0.34%
cases:20.75%
controls:1.54%
cases:28.23%
controls:2.95%
20
57
157
1710
16
31
161
1736
—
24
0
153
1767
13
6
163
1755
33
26
126
1666
35
43
89
1413
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.0e-01
8.3e-01
2.1e+00
4.7e+00
2.8e+00
9.0e-01
4.7e-01
cases:43.50%
controls:36.39%
cases:45.20%
controls:26.43%
cases:32.20%
controls:5.26%
cases:35.03%
controls:0.51%
cases:42.61%
controls:4.43%
cases:46.54%
controls:26.06%
cases:57.26%
controls:45.47%
77
643
100
1124
80
467
97
1300
57
93
120
1674
62
9
115
1758
75
78
101
1683
74
441
85
1251
71
662
53
794
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
9.6e-01
1.7e+00
2.7e+00
—
3.2e+00
1.7e+00
1.1e+00
cases:12.43%
controls:5.15%
cases:10.17%
controls:2.09%
cases:3.95%
controls:0.28%
—
—
cases:6.82%
controls:0.28%
cases:9.43%
controls:1.95%
cases:16.13%
controls:6.04%
22
91
155
1676
18
37
159
1730
7
5
170
1762
—
12
5
164
1756
15
33
144
1659
20
88
104
1368
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.1e-01
8.1e-01
2.1e+00
4.7e+00
2.7e+00
8.9e-01
4.7e-01
cases:44.07%
controls:36.73%
cases:45.20%
controls:26.94%
cases:32.20%
controls:5.38%
cases:35.03%
controls:0.51%
cases:42.61%
controls:4.60%
cases:46.54%
controls:26.36%
cases:57.26%
controls:45.67%
78
649
99
1118
80
476
97
1291
57
95
120
1672
62
9
115
1758
75
81
101
1680
74
446
85
1246
71
665
53
791
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.0e+00
1.5e+00
2.9e+00
—
3.2e+00
1.4e+00
1.0e+00
cases:27.68%
controls:11.94%
cases:23.73%
controls:6.56%
cases:19.21%
controls:1.30%
—
—
cases:21.59%
controls:1.08%
cases:18.24%
controls:5.14%
cases:29.03%
controls:12.91%
49
211
128
1556
42
116
135
1651
34
23
143
1744
—
38
19
138
1742
29
87
130
1605
36
188
88
1268
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
7.5e-01
1.5e+00
3.0e+00
—
3.3e+00
1.6e+00
7.8e-01
cases:25.42%
controls:13.92%
cases:19.77%
controls:5.38%
cases:11.86%
controls:0.68%
—
—
cases:18.18%
controls:0.80%
cases:21.38%
controls:5.20%
cases:25.81%
controls:13.80%
45
246
132
1521
35
95
142
1672
21
12
156
1755
—
32
14
144
1747
34
88
125
1604
32
201
92
1255
Thorax X-ray examination
GD1AA [2001303617]
1.1e+00
1.8e+00
1.9e+00
1.0e+50
2.9e+00
1.8e+00
1.2e+00
cases:20.34%
controls:7.75%
cases:13.56%
controls:2.49%
cases:3.95%
controls:0.62%
cases:6.21%
controls:0.00%
cases:5.11%
controls:0.28%
cases:11.95%
controls:2.19%
cases:20.16%
controls:7.07%
36
137
141
1630
24
44
153
1723
7
11
170
1756
11
0
166
1767
9
5
167
1756
19
37
140
1655
25
103
99
1353
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.3e-01
6.4e-01
2.0e+00
4.7e+00
2.4e+00
7.4e-01
3.5e-01
cases:33.90%
controls:26.88%
cases:32.77%
controls:20.37%
cases:26.55%
controls:4.64%
cases:24.29%
controls:0.28%
cases:31.25%
controls:3.80%
cases:36.48%
controls:21.45%
cases:48.39%
controls:39.77%
60
475
117
1292
58
360
119
1407
47
82
130
1685
43
5
134
1762
55
67
121
1694
58
363
101
1329
60
579
64
877
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
1.3e+00
1.6e+00
2.8e+00
—
3.1e+00
1.8e+00
7.5e-01
cases:9.04%
controls:2.72%
cases:9.04%
controls:1.92%
cases:5.08%
controls:0.34%
—
—
cases:7.95%
controls:0.40%
cases:11.32%
controls:2.01%
cases:15.32%
controls:7.90%
16
48
161
1719
16
34
161
1733
9
6
168
1761
—
14
7
162
1754
18
34
141
1658
19
115
105
1341
Inpatient Hospital
21 [8717]
7.9e-01
1.4e+00
2.3e+00
1.0e+50
3.2e+00
1.9e+00
1.0e+00
cases:46.33%
controls:28.24%
cases:21.47%
controls:6.51%
cases:8.47%
controls:0.91%
cases:19.77%
controls:0.00%
cases:17.05%
controls:0.85%
cases:27.67%
controls:5.67%
cases:37.90%
controls:17.72%
82
499
95
1268
38
115
139
1652
15
16
162
1751
35
0
142
1767
30
15
146
1746
44
96
115
1596
47
258
77
1198
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
1.1e+00
1.6e+00
3.0e+00
1.0e+50
3.4e+00
1.4e+00
6.7e-01
cases:12.43%
controls:4.53%
cases:11.30%
controls:2.60%
cases:7.34%
controls:0.40%
cases:2.82%
controls:0.00%
cases:9.66%
controls:0.34%
cases:10.06%
controls:2.78%
cases:11.29%
controls:6.11%
22
80
155
1687
20
46
157
1721
13
7
164
1760
5
0
172
1767
17
6
159
1755
16
47
143
1645
14
89
110
1367
Inpatient Visit
IP [9201]
7.3e-01
1.2e+00
3.1e+00
1.0e+50
3.2e+00
1.7e+00
1.2e+00
cases:14.12%
controls:7.36%
cases:10.73%
controls:3.62%
cases:6.21%
controls:0.28%
cases:6.78%
controls:0.00%
cases:9.66%
controls:0.45%
cases:15.09%
controls:3.13%
cases:20.16%
controls:7.07%
25
130
152
1637
19
64
158
1703
11
5
166
1762
12
0
165
1767
17
8
159
1753
24
53
135
1639
25
103
99
1353
CBC panel - Blood by Automated count
58410-2 [40761511]
4.3e-01
8.4e-01
1.8e+00
4.3e+00
2.6e+00
8.2e-01
3.7e-01
cases:46.33%
controls:36.05%
cases:40.68%
controls:22.81%
cases:21.47%
controls:4.36%
cases:22.03%
controls:0.40%
cases:32.39%
controls:3.58%
cases:37.11%
controls:20.69%
cases:49.19%
controls:40.18%
82
637
95
1130
72
403
105
1364
38
77
139
1690
39
7
138
1760
57
63
119
1698
59
350
100
1342
61
585
63
871
Outpatient Visit
OP [9202]
6.8e-01
6.8e-01
1.1e+00
5.2e+00
1.4e+00
1.1e+00
9.4e-01
cases:81.92%
controls:69.61%
cases:66.10%
controls:49.58%
cases:28.25%
controls:11.09%
cases:35.03%
controls:0.28%
cases:34.09%
controls:11.70%
cases:75.47%
controls:51.54%
cases:88.71%
controls:75.41%
145
1230
32
537
117
876
60
891
50
196
127
1571
62
5
115
1762
60
206
116
1555
120
872
39
820
110
1098
14
358
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.1e-01
7.0e-01
2.0e+00
4.3e+00
2.5e+00
6.7e-01
3.6e-01
cases:47.46%
controls:39.90%
cases:48.02%
controls:31.52%
cases:35.03%
controls:7.07%
cases:32.20%
controls:0.62%
cases:41.48%
controls:5.45%
cases:47.17%
controls:31.32%
cases:59.68%
controls:50.69%
84
705
93
1062
85
557
92
1210
62
125
115
1642
57
11
120
1756
73
96
103
1665
75
530
84
1162
74
738
50
718
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.8e-01
7.2e-01
1.8e+00
4.5e+00
2.3e+00
7.8e-01
4.0e-01
cases:33.90%
controls:27.84%
cases:35.03%
controls:20.83%
cases:25.42%
controls:5.09%
cases:20.34%
controls:0.28%
cases:30.11%
controls:4.20%
cases:36.48%
controls:20.86%
cases:44.35%
controls:34.75%
60
492
117
1275
62
368
115
1399
45
90
132
1677
36
5
141
1762
53
74
123
1687
58
353
101
1339
55
506
69
950
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
7.8e-01
1.8e+00
2.3e+00
1.0e+50
3.3e+00
1.4e+00
1.4e+00
cases:11.86%
controls:5.83%
cases:10.17%
controls:1.81%
cases:5.65%
controls:0.62%
cases:7.91%
controls:0.00%
cases:9.66%
controls:0.40%
cases:8.18%
controls:2.25%
cases:19.35%
controls:5.56%
21
103
156
1664
18
32
159
1735
10
11
167
1756
14
0
163
1767
17
7
159
1754
13
38
146
1654
24
81
100
1375
INR in Blood by Coagulation assay
34714-6 [3032080]
1.1e+00
1.6e+00
2.3e+00
—
2.5e+00
1.6e+00
1.0e+00
cases:25.42%
controls:9.79%
cases:19.21%
controls:4.64%
cases:12.43%
controls:1.41%
—
—
cases:13.64%
controls:1.31%
cases:16.98%
controls:3.96%
cases:23.39%
controls:10.10%
45
173
132
1594
34
82
143
1685
22
25
155
1742
—
24
23
152
1738
27
67
132
1625
29
147
95
1309
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.4e-01
1.5e+00
2.6e+00
—
3.0e+00
1.5e+00
8.8e-01
cases:34.46%
controls:21.68%
cases:37.29%
controls:11.66%
cases:25.99%
controls:2.66%
—
—
cases:28.98%
controls:2.04%
cases:36.48%
controls:11.47%
cases:43.55%
controls:24.24%
61
383
116
1384
66
206
111
1561
46
47
131
1720
—
51
36
125
1725
58
194
101
1498
54
353
70
1103
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
7.9e-01
2.0e+00
2.6e+00
—
3.6e+00
1.8e+00
7.9e-01
cases:13.56%
controls:6.62%
cases:17.51%
controls:2.77%
cases:5.08%
controls:0.40%
—
—
cases:9.66%
controls:0.28%
cases:13.84%
controls:2.60%
cases:19.35%
controls:9.82%
24
117
153
1650
31
49
146
1718
9
7
168
1760
—
17
5
159
1756
22
44
137
1648
24
143
100
1313
Emergency Room Visit
ER [9203]
1.1e+00
1.4e+00
2.0e+00
—
2.6e+00
1.6e+00
1.2e+00
cases:55.37%
controls:29.20%
cases:25.99%
controls:7.70%
cases:11.86%
controls:1.81%
—
—
cases:13.07%
controls:1.08%
cases:29.56%
controls:7.51%
cases:48.39%
controls:22.18%
98
516
79
1251
46
136
131
1631
21
32
156
1735
—
23
19
153
1742
47
127
112
1565
60
323
64
1133
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.8e-01
1.5e+00
2.2e+00
—
2.6e+00
1.5e+00
1.3e+00
cases:16.38%
controls:7.53%
cases:16.38%
controls:4.36%
cases:10.17%
controls:1.19%
—
—
cases:10.23%
controls:0.85%
cases:17.61%
controls:4.61%
cases:25.81%
controls:8.52%
29
133
148
1634
29
77
148
1690
18
21
159
1746
—
18
15
158
1746
28
78
131
1614
32
124
92
1332
Monocytes/Leukocytes in Blood
26485-3 [3019069]
7.7e-01
1.4e+00
2.3e+00
—
2.8e+00
1.4e+00
1.2e+00
cases:21.47%
controls:11.26%
cases:22.60%
controls:6.51%
cases:14.12%
controls:1.70%
—
—
cases:16.48%
controls:1.14%
cases:22.64%
controls:6.62%
cases:32.26%
controls:12.16%
38
199
139
1568
40
115
137
1652
25
30
152
1737
—
29
20
147
1741
36
112
123
1580
40
177
84
1279
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
7.7e-01
1.4e+00
2.3e+00
—
2.8e+00
1.4e+00
1.2e+00
cases:21.47%
controls:11.21%
cases:22.60%
controls:6.51%
cases:14.12%
controls:1.70%
—
—
cases:16.48%
controls:1.14%
cases:22.64%
controls:6.62%
cases:32.26%
controls:12.23%
38
198
139
1569
40
115
137
1652
25
30
152
1737
—
29
20
147
1741
36
112
123
1580
40
178
84
1278
Basophils/Leukocytes in Blood
30180-4 [3022096]
7.1e-01
1.5e+00
2.3e+00
—
2.8e+00
1.4e+00
1.3e+00
cases:20.34%
controls:11.15%
cases:22.60%
controls:6.34%
cases:14.12%
controls:1.70%
—
—
cases:15.91%
controls:1.14%
cases:22.64%
controls:6.50%
cases:33.06%
controls:12.29%
36
197
141
1570
40
112
137
1655
25
30
152
1737
—
28
20
148
1741
36
110
123
1582
41
179
83
1277
Monocytes [#/volume] in Blood
26484-6 [3001604]
6.9e-01
1.5e+00
2.3e+00
—
2.8e+00
1.3e+00
1.3e+00
cases:22.03%
controls:12.39%
cases:24.29%
controls:6.73%
cases:14.69%
controls:1.70%
—
—
cases:16.48%
controls:1.19%
cases:22.64%
controls:7.21%
cases:36.29%
controls:13.60%
39
219
138
1548
43
119
134
1648
26
30
151
1737
—
29
21
147
1740
36
122
123
1570
45
198
79
1258
Basophils [#/volume] in Blood
26444-0 [3006315]
7.0e-01
1.5e+00
2.3e+00
—
2.8e+00
1.3e+00
1.3e+00
cases:22.03%
controls:12.34%
cases:24.29%
controls:6.73%
cases:14.69%
controls:1.70%
—
—
cases:16.48%
controls:1.19%
cases:22.64%
controls:7.21%
cases:36.29%
controls:13.67%
39
218
138
1549
43
119
134
1648
26
30
151
1737
—
29
21
147
1740
36
122
123
1570
45
199
79
1257
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
9.9e-01
1.4e+00
2.2e+00
1.0e+50
2.9e+00
1.3e+00
9.9e-01
cases:19.21%
controls:8.15%
cases:11.30%
controls:3.06%
cases:5.08%
controls:0.57%
cases:11.30%
controls:0.00%
cases:9.66%
controls:0.57%
cases:11.95%
controls:3.49%
cases:18.55%
controls:7.83%
34
144
143
1623
20
54
157
1713
9
10
168
1757
20
0
157
1767
17
10
159
1751
19
59
140
1633
23
114
101
1342
Upper gastrointestinal surgery
106 [44777669]
1.1e+00
1.6e+00
1.9e+00
—
2.3e+00
1.8e+00
1.1e+00
cases:19.77%
controls:7.92%
cases:14.12%
controls:3.11%
cases:5.08%
controls:0.79%
—
—
cases:3.98%
controls:0.40%
cases:13.21%
controls:2.54%
cases:18.55%
controls:6.94%
35
140
142
1627
25
55
152
1712
9
14
168
1753
—
7
7
169
1754
21
43
138
1649
23
101
101
1355
Bacteria identified in Urine by Culture
630-4 [3026008]
9.1e-01
1.4e+00
2.0e+00
1.0e+50
3.2e+00
1.2e+00
9.0e-01
cases:13.56%
controls:5.94%
cases:9.60%
controls:2.49%
cases:3.95%
controls:0.57%
cases:5.08%
controls:0.00%
cases:7.95%
controls:0.34%
cases:8.81%
controls:2.72%
cases:16.13%
controls:7.28%
24
105
153
1662
17
44
160
1723
7
10
170
1757
9
0
168
1767
14
6
162
1755
14
46
145
1646
20
106
104
1350
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.1e-01
1.4e+00
2.2e+00
—
2.7e+00
1.3e+00
1.3e+00
cases:23.16%
controls:12.96%
cases:24.29%
controls:7.13%
cases:14.69%
controls:1.81%
—
—
cases:17.05%
controls:1.31%
cases:22.64%
controls:7.45%
cases:37.10%
controls:14.29%
41
229
136
1538
43
126
134
1641
26
32
151
1735
—
30
23
146
1738
36
126
123
1566
46
208
78
1248
calcium (different salts in combination); oral
A12AA20 [21600872]
1.3e+00
1.4e+00
1.6e+00
—
2.1e+00
1.8e+00
1.5e+00
cases:22.03%
controls:7.41%
cases:20.90%
controls:6.23%
cases:6.78%
controls:1.47%
—
—
cases:12.50%
controls:1.70%
cases:28.30%
controls:5.91%
cases:29.03%
controls:8.52%
39
131
138
1636
37
110
140
1657
12
26
165
1741
—
22
30
154
1731
45
100
114
1592
36
124
88
1332
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.2e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.7e-01
2.6e-01
cases:48.59%
controls:43.24%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.70%
cases:48.43%
controls:34.69%
cases:61.29%
controls:54.88%
86
764
91
1003
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
118
101
1643
77
587
82
1105
76
799
48
657
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.1e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.7e-01
2.6e-01
cases:48.59%
controls:43.29%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.70%
cases:48.43%
controls:34.69%
cases:61.29%
controls:55.01%
86
765
91
1002
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
118
101
1643
77
587
82
1105
76
801
48
655
MCH [Entitic mass]
28539-5 [3035941]
2.2e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.7e-01
2.6e-01
cases:48.59%
controls:43.12%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.70%
cases:48.43%
controls:34.75%
cases:61.29%
controls:54.88%
86
762
91
1005
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
118
101
1643
77
588
82
1104
76
799
48
657
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.2e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.6e-01
2.6e-01
cases:48.59%
controls:43.12%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.70%
cases:48.43%
controls:34.81%
cases:61.29%
controls:54.88%
86
762
91
1005
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
118
101
1643
77
589
82
1103
76
799
48
657
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.2e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.6e-01
2.6e-01
cases:48.59%
controls:43.18%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.70%
cases:48.43%
controls:34.81%
cases:61.29%
controls:54.88%
86
763
91
1004
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
118
101
1643
77
589
82
1103
76
799
48
657
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.2e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.6e-01
2.7e-01
cases:48.59%
controls:43.18%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.70%
cases:48.43%
controls:34.87%
cases:61.29%
controls:54.81%
86
763
91
1004
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
118
101
1643
77
590
82
1102
76
798
48
658
Platelets [#/volume] in Blood
26515-7 [3007461]
2.2e-01
6.2e-01
1.8e+00
4.3e+00
2.3e+00
5.7e-01
2.7e-01
cases:48.59%
controls:43.12%
cases:49.72%
controls:34.80%
cases:34.46%
controls:8.09%
cases:32.20%
controls:0.62%
cases:42.61%
controls:6.76%
cases:48.43%
controls:34.75%
cases:61.29%
controls:54.81%
86
762
91
1005
88
615
89
1152
61
143
116
1624
57
11
120
1756
75
119
101
1642
77
588
82
1104
76
798
48
658
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.0e-01
7.9e-01
1.8e+00
4.0e+00
2.2e+00
7.7e-01
3.0e-01
cases:42.37%
controls:37.63%
cases:44.63%
controls:26.77%
cases:25.42%
controls:5.49%
cases:16.38%
controls:0.34%
cases:30.11%
controls:4.43%
cases:44.65%
controls:27.19%
cases:55.65%
controls:48.08%
75
665
102
1102
79
473
98
1294
45
97
132
1670
29
6
148
1761
53
78
123
1683
71
460
88
1232
69
700
55
756
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
7.9e-01
2.6e+00
2.8e+00
—
—
2.5e+00
1.6e+00
cases:4.52%
controls:2.09%
cases:7.91%
controls:0.62%
cases:4.52%
controls:0.28%
—
—
—
—
cases:6.92%
controls:0.59%
cases:10.48%
controls:2.27%
8
37
169
1730
14
11
163
1756
8
5
169
1762
—
—
11
10
148
1682
13
33
111
1423
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
1.5e+00
2.4e+00
—
—
—
3.1e+00
2.4e+00
cases:6.78%
controls:1.53%
cases:9.04%
controls:0.85%
—
—
—
—
—
—
cases:15.72%
controls:0.83%
cases:19.35%
controls:2.13%
12
27
165
1740
16
15
161
1752
—
—
—
25
14
134
1678
24
31
100
1425
Outpatient Hospital
22 [8756]
8.1e-01
1.4e+00
1.8e+00
1.0e+50
2.6e+00
1.8e+00
1.1e+00
cases:38.42%
controls:21.79%
cases:16.38%
controls:4.47%
cases:5.65%
controls:1.02%
cases:7.91%
controls:0.00%
cases:8.52%
controls:0.68%
cases:19.50%
controls:3.84%
cases:29.84%
controls:12.77%
68
385
109
1382
29
79
148
1688
10
18
167
1749
14
0
163
1767
15
12
161
1749
31
65
128
1627
37
186
87
1270
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
6.3e-01
1.4e+00
2.3e+00
—
2.8e+00
1.4e+00
1.3e+00
cases:20.34%
controls:12.00%
cases:23.16%
controls:6.73%
cases:14.12%
controls:1.70%
—
—
cases:16.48%
controls:1.19%
cases:22.64%
controls:6.74%
cases:34.68%
controls:12.43%
36
212
141
1555
41
119
136
1648
25
30
152
1737
—
29
21
147
1740
36
114
123
1578
43
181
81
1275
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
6.7e-01
1.0e+00
2.4e+00
—
3.0e+00
1.3e+00
7.7e-01
cases:25.99%
controls:15.22%
cases:17.51%
controls:7.07%
cases:6.78%
controls:0.68%
—
—
cases:13.64%
controls:0.80%
cases:21.38%
controls:6.97%
cases:33.06%
controls:18.54%
46
269
131
1498
31
125
146
1642
12
12
165
1755
—
24
14
152
1747
34
118
125
1574
41
270
83
1186
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
6.3e-01
1.4e+00
2.2e+00
1.0e+50
2.4e+00
1.3e+00
1.1e+00
cases:24.86%
controls:14.94%
cases:27.12%
controls:8.66%
cases:17.51%
controls:2.26%
cases:7.91%
controls:0.00%
cases:17.05%
controls:1.82%
cases:25.79%
controls:8.45%
cases:35.48%
controls:15.80%
44
264
133
1503
48
153
129
1614
31
40
146
1727
14
0
163
1767
30
32
146
1729
41
143
118
1549
44
230
80
1226
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
5.9e-01
1.4e+00
2.3e+00
—
2.7e+00
1.3e+00
1.2e+00
cases:21.47%
controls:13.13%
cases:24.29%
controls:7.07%
cases:14.69%
controls:1.75%
—
—
cases:16.48%
controls:1.25%
cases:22.01%
controls:7.27%
cases:35.48%
controls:13.94%
38
232
139
1535
43
125
134
1642
26
31
151
1736
—
29
22
147
1739
35
123
124
1569
44
203
80
1253
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
6.4e-01
1.4e+00
2.2e+00
—
2.7e+00
1.3e+00
1.3e+00
cases:19.77%
controls:11.49%
cases:22.03%
controls:6.68%
cases:13.56%
controls:1.64%
—
—
cases:14.77%
controls:1.19%
cases:21.38%
controls:6.74%
cases:33.87%
controls:12.09%
35
203
142
1564
39
118
138
1649
24
29
153
1738
—
26
21
150
1740
34
114
125
1578
42
176
82
1280
Gastroenterology
10 [38004455]
1.1e+00
1.5e+00
2.8e+00
—
1.9e+00
1.6e+00
9.2e-01
cases:14.69%
controls:5.60%
cases:7.91%
controls:1.87%
cases:4.52%
controls:0.28%
—
—
cases:4.55%
controls:0.74%
cases:10.06%
controls:2.13%
cases:13.71%
controls:5.98%
26
99
151
1668
14
33
163
1734
8
5
169
1762
—
8
13
168
1748
16
36
143
1656
17
87
107
1369
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
6.0e-01
1.6e+00
1.7e+00
—
3.2e+00
1.5e+00
8.8e-01
cases:15.25%
controls:9.00%
cases:18.08%
controls:4.19%
cases:4.52%
controls:0.85%
—
—
cases:10.80%
controls:0.51%
cases:18.24%
controls:4.73%
cases:25.81%
controls:12.64%
27
159
150
1608
32
74
145
1693
8
15
169
1752
—
19
9
157
1752
29
80
130
1612
32
184
92
1272
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.7e+00
2.4e+00
—
1.0e+50
—
2.7e+00
1.9e+00
cases:7.34%
controls:1.41%
cases:7.34%
controls:0.68%
—
—
cases:4.52%
controls:0.00%
—
—
cases:10.06%
controls:0.71%
cases:9.68%
controls:1.51%
13
25
164
1742
13
12
164
1755
—
8
0
169
1767
—
16
12
143
1680
12
22
112
1434
Short blood count panel - Blood
55429-5 [40758558]
2.2e-01
1.3e+00
2.2e+00
—
2.7e+00
1.4e+00
1.0e+00
cases:9.04%
controls:7.36%
cases:11.86%
controls:3.62%
cases:5.65%
controls:0.68%
—
—
cases:6.82%
controls:0.51%
cases:11.32%
controls:2.96%
cases:19.35%
controls:8.10%
16
130
161
1637
21
64
156
1703
10
12
167
1755
—
12
9
164
1752
18
50
141
1642
24
118
100
1338
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.8e+00
2.6e+00
—
—
—
2.4e+00
1.7e+00
cases:6.78%
controls:1.19%
cases:6.21%
controls:0.51%
—
—
—
—
—
—
cases:4.40%
controls:0.41%
cases:7.26%
controls:1.37%
12
21
165
1746
11
9
166
1758
—
—
—
7
7
152
1685
9
20
115
1436
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
2.5e+00
—
1.0e+50
—
1.0e+50
3.2e+00
2.7e+00
cases:3.39%
controls:0.28%
—
—
cases:2.82%
controls:0.00%
—
—
cases:2.84%
controls:0.00%
cases:6.92%
controls:0.30%
cases:4.84%
controls:0.34%
6
5
171
1762
—
5
0
172
1767
—
5
0
171
1761
11
5
148
1687
6
5
118
1451
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.2e-01
9.8e-01
2.5e+00
—
3.2e+00
1.4e+00
1.3e+00
cases:9.04%
controls:5.60%
cases:7.34%
controls:2.89%
cases:5.65%
controls:0.51%
—
—
cases:6.82%
controls:0.28%
cases:7.55%
controls:2.01%
cases:16.94%
controls:5.08%
16
99
161
1668
13
51
164
1716
10
9
167
1758
—
12
5
164
1756
12
34
147
1658
21
74
103
1382
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.4e+00
2.7e+00
—
—
—
2.4e+00
1.8e+00
cases:13.56%
controls:3.85%
cases:8.47%
controls:0.62%
—
—
—
—
—
—
cases:8.81%
controls:0.83%
cases:13.71%
controls:2.61%
24
68
153
1699
15
11
162
1756
—
—
—
14
14
145
1678
17
38
107
1418
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
9.3e-01
1.9e+00
1.9e+00
—
3.1e+00
1.4e+00
9.9e-01
cases:18.08%
controls:8.04%
cases:16.95%
controls:3.06%
cases:3.39%
controls:0.51%
—
—
cases:7.95%
controls:0.40%
cases:10.69%
controls:2.84%
cases:20.16%
controls:8.59%
32
142
145
1625
30
54
147
1713
6
9
171
1758
—
14
7
162
1754
17
48
142
1644
25
125
99
1331
Emergency Medicine
93 [38004510]
9.7e-01
1.1e+00
2.7e+00
—
2.0e+00
1.4e+00
6.5e-01
cases:29.94%
controls:13.92%
cases:18.08%
controls:6.96%
cases:13.56%
controls:1.02%
—
—
cases:6.25%
controls:0.85%
cases:22.01%
controls:6.74%
cases:31.45%
controls:19.30%
53
246
124
1521
32
123
145
1644
24
18
153
1749
—
11
15
165
1746
35
114
124
1578
39
281
85
1175
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.1e+00
1.6e+00
2.9e+00
—
—
1.6e+00
9.3e-01
cases:16.38%
controls:6.40%
cases:11.30%
controls:2.55%
cases:8.47%
controls:0.51%
—
—
—
—
cases:8.81%
controls:1.95%
cases:14.52%
controls:6.25%
29
113
148
1654
20
45
157
1722
15
9
162
1758
—
—
14
33
145
1659
18
91
106
1365
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.4e+00
2.6e+00
—
—
—
2.6e+00
1.4e+00
cases:8.47%
controls:2.32%
cases:12.43%
controls:1.02%
—
—
—
—
—
—
cases:12.58%
controls:1.00%
cases:11.29%
controls:3.09%
15
41
162
1726
22
18
155
1749
—
—
—
20
17
139
1675
14
45
110
1411
General Practice
1 [38004446]
7.1e-01
1.4e+00
1.5e+00
—
3.5e+00
1.6e+00
8.8e-01
cases:20.90%
controls:11.49%
cases:11.30%
controls:3.17%
cases:2.82%
controls:0.62%
—
—
cases:15.34%
controls:0.57%
cases:19.50%
controls:4.73%
cases:23.39%
controls:11.20%
37
203
140
1564
20
56
157
1711
5
11
172
1756
—
27
10
149
1751
31
80
128
1612
29
163
95
1293
Normoblasts [#/volume] in Blood
715-3 [3021589]
4.8e-01
1.2e+00
2.2e+00
—
2.3e+00
1.2e+00
1.1e+00
cases:15.82%
controls:10.41%
cases:21.47%
controls:7.87%
cases:13.56%
controls:1.70%
—
—
cases:16.48%
controls:1.87%
cases:22.01%
controls:8.04%
cases:33.87%
controls:14.70%
28
184
149
1583
38
139
139
1628
24
30
153
1737
—
29
33
147
1728
35
136
124
1556
42
214
82
1242
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.3e+00
2.7e+00
—
—
—
2.6e+00
1.3e+00
cases:8.47%
controls:2.38%
cases:14.12%
controls:1.13%
—
—
—
—
—
—
cases:13.21%
controls:1.06%
cases:12.10%
controls:3.57%
15
42
162
1725
25
20
152
1747
—
—
—
21
18
138
1674
15
52
109
1404
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.6e+00
1.9e+00
—
—
—
2.8e+00
1.5e+00
cases:9.04%
controls:2.04%
cases:6.21%
controls:0.96%
—
—
—
—
—
—
cases:10.06%
controls:0.65%
cases:9.68%
controls:2.27%
16
36
161
1731
11
17
166
1750
—
—
—
16
11
143
1681
12
33
112
1423
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
6.4e-01
1.1e+00
1.6e+00
1.0e+50
2.8e+00
9.4e-01
7.6e-01
cases:28.81%
controls:17.54%
cases:22.03%
controls:8.38%
cases:7.91%
controls:1.75%
cases:7.34%
controls:0.00%
cases:11.93%
controls:0.85%
cases:16.98%
controls:7.39%
cases:33.87%
controls:19.37%
51
310
126
1457
39
148
138
1619
14
31
163
1736
13
0
164
1767
21
15
155
1746
27
125
132
1567
42
282
82
1174
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.6e-01
1.3e+00
1.8e+00
—
2.8e+00
1.1e+00
7.4e-01
cases:27.12%
controls:17.54%
cases:22.03%
controls:7.24%
cases:9.04%
controls:1.58%
—
—
cases:13.64%
controls:0.97%
cases:18.87%
controls:6.97%
cases:31.45%
controls:17.93%
48
310
129
1457
39
128
138
1639
16
28
161
1739
—
24
17
152
1744
30
118
129
1574
39
261
85
1195
Laboratory Visit
OMOP4822461 [32036]
1.6e-01
3.8e-01
1.6e+00
4.2e+00
1.9e+00
4.1e-01
1.3e-01
cases:51.41%
controls:47.31%
cases:53.67%
controls:44.26%
cases:41.24%
controls:12.45%
cases:38.98%
controls:0.96%
cases:47.16%
controls:11.41%
cases:53.46%
controls:43.20%
cases:63.71%
controls:60.65%
91
836
86
931
95
782
82
985
73
220
104
1547
69
17
108
1750
83
201
93
1560
85
731
74
961
79
883
45
573
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.2e-01
1.2e+00
2.2e+00
—
2.5e+00
9.2e-01
7.9e-01
cases:29.94%
controls:20.32%
cases:25.42%
controls:9.34%
cases:9.60%
controls:1.19%
—
—
cases:14.20%
controls:1.31%
cases:21.38%
controls:9.81%
cases:38.71%
controls:22.25%
53
359
124
1408
45
165
132
1602
17
21
160
1746
—
25
23
151
1738
34
166
125
1526
48
324
76
1132
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
7.0e-01
8.6e-01
2.3e+00
—
2.3e+00
2.0e+00
1.0e+00
cases:11.86%
controls:6.28%
cases:5.08%
controls:2.21%
cases:6.21%
controls:0.68%
—
—
cases:3.41%
controls:0.34%
cases:11.32%
controls:1.77%
cases:15.32%
controls:6.25%
21
111
156
1656
9
39
168
1728
11
12
166
1755
—
6
6
170
1755
18
30
141
1662
19
91
105
1365
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.2e+00
2.6e+00
—
—
—
2.4e+00
1.3e+00
cases:9.04%
controls:2.89%
cases:15.25%
controls:1.36%
—
—
—
—
—
—
cases:13.21%
controls:1.30%
cases:12.90%
controls:3.78%
16
51
161
1716
27
24
150
1743
—
—
—
21
22
138
1670
16
55
108
1401
pH of Venous blood
2746-6 [3012544]
7.9e-01
1.5e+00
2.5e+00
1.0e+50
—
1.9e+00
1.4e+00
cases:5.08%
controls:2.38%
cases:6.21%
controls:1.41%
cases:3.39%
controls:0.28%
cases:3.95%
controls:0.00%
—
—
cases:6.29%
controls:0.95%
cases:11.29%
controls:3.16%
9
42
168
1725
11
25
166
1742
6
5
171
1762
7
0
170
1767
—
10
16
149
1676
14
46
110
1410
Medical doctor
Z2221 [2001311556]
1.1e+00
1.9e+00
—
—
—
2.3e+00
2.0e+00
cases:10.73%
controls:3.79%
cases:6.21%
controls:0.96%
—
—
—
—
—
—
cases:6.29%
controls:0.65%
cases:10.48%
controls:1.58%
19
67
158
1700
11
17
166
1750
—
—
—
10
11
149
1681
13
23
111
1433
Chronic kidney disease, unspecified
N18.9 [45553438]
2.5e+00
—
—
—
—
2.6e+00
2.2e+00
cases:4.52%
controls:0.40%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.35%
cases:4.84%
controls:0.55%
8
7
169
1760
—
—
—
—
7
6
152
1686
6
8
118
1448
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-2.6e-01
6.6e-02
1.3e+00
4.1e+00
1.8e+00
9.3e-02
-1.2e-01
cases:27.68%
controls:33.22%
cases:25.99%
controls:24.73%
cases:18.64%
controls:5.83%
cases:14.69%
controls:0.28%
cases:21.02%
controls:4.09%
cases:25.79%
controls:24.05%
cases:37.90%
controls:40.73%
49
587
128
1180
46
437
131
1330
33
103
144
1664
26
5
151
1762
37
72
139
1689
41
407
118
1285
47
593
77
863
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
8.4e-01
1.5e+00
2.5e+00
1.0e+50
—
1.9e+00
1.3e+00
cases:5.08%
controls:2.26%
cases:5.65%
controls:1.36%
cases:3.39%
controls:0.28%
cases:3.95%
controls:0.00%
—
—
cases:6.29%
controls:0.95%
cases:10.48%
controls:3.09%
9
40
168
1727
10
24
167
1743
6
5
171
1762
7
0
170
1767
—
10
16
149
1676
13
45
111
1411
Anaemia, unspecified
D64.9 [45600610]
2.1e+00
3.0e+00
—
1.0e+50
—
—
2.0e+00
cases:5.08%
controls:0.62%
cases:5.65%
controls:0.28%
—
—
cases:2.82%
controls:0.00%
—
—
—
—
cases:6.45%
controls:0.96%
9
11
168
1756
10
5
167
1762
—
5
0
172
1767
—
—
8
14
116
1442
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
2.1e+00
2.1e+00
—
—
1.0e+50
2.9e+00
1.4e+00
cases:6.21%
controls:0.79%
cases:3.95%
controls:0.51%
—
—
—
—
cases:6.25%
controls:0.00%
cases:8.81%
controls:0.53%
cases:6.45%
controls:1.72%
11
14
166
1753
7
9
170
1758
—
—
11
0
165
1761
14
9
145
1683
8
25
116
1431
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
9.0e-01
1.5e+00
1.9e+00
—
2.7e+00
9.7e-01
7.2e-01
cases:18.64%
controls:8.49%
cases:15.25%
controls:3.90%
cases:4.52%
controls:0.68%
—
—
cases:7.95%
controls:0.57%
cases:10.06%
controls:4.08%
cases:21.77%
controls:11.95%
33
150
144
1617
27
69
150
1698
8
12
169
1755
—
14
10
162
1751
16
69
143
1623
27
174
97
1282
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
9.4e-01
1.7e+00
1.8e+00
—
3.2e+00
1.1e+00
7.7e-01
cases:15.82%
controls:6.85%
cases:14.12%
controls:2.94%
cases:3.39%
controls:0.57%
—
—
cases:6.82%
controls:0.28%
cases:8.18%
controls:2.84%
cases:16.94%
controls:8.65%
28
121
149
1646
25
52
152
1715
6
10
171
1757
—
12
5
164
1756
13
48
146
1644
21
126
103
1330
alfacalcidol; oral, parenteral
A11CC03 [21600818]
3.4e+00
—
—
—
—
—
3.6e+00
cases:7.91%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:12.90%
controls:0.41%
14
5
163
1762
—
—
—
—
—
16
6
108
1450
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
8.3e-01
2.0e+00
—
1.0e+50
1.0e+50
3.2e+00
1.7e+00
cases:2.82%
controls:1.25%
cases:3.95%
controls:0.57%
—
—
cases:2.82%
controls:0.00%
cases:6.25%
controls:0.00%
cases:6.92%
controls:0.30%
cases:5.65%
controls:1.03%
5
22
172
1745
7
10
170
1757
—
5
0
172
1767
11
0
165
1761
11
5
148
1687
7
15
117
1441
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.2e+00
2.4e+00
—
—
1.0e+50
2.6e+00
1.9e+00
cases:6.78%
controls:2.21%
cases:6.21%
controls:0.62%
—
—
—
—
cases:6.25%
controls:0.00%
cases:6.92%
controls:0.53%
cases:10.48%
controls:1.79%
12
39
165
1728
11
11
166
1756
—
—
11
0
165
1761
11
9
148
1683
13
26
111
1430
Abdominal CT examination
JN3AD [2001305554]
2.1e+00
2.5e+00
—
—
1.0e+50
2.2e+00
-1.0e+50
cases:6.78%
controls:0.85%
cases:6.21%
controls:0.57%
—
—
—
—
cases:2.84%
controls:0.00%
cases:3.77%
controls:0.41%
cases:0.00%
controls:1.92%
12
15
165
1752
11
10
166
1757
—
—
5
0
171
1761
6
7
153
1685
0
28
124
1428
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
6.8e-01
1.0e+00
2.3e+00
—
2.1e+00
1.4e+00
5.8e-01
cases:17.51%
controls:9.68%
cases:10.17%
controls:3.96%
cases:7.34%
controls:0.79%
—
—
cases:3.98%
controls:0.51%
cases:10.69%
controls:2.90%
cases:16.13%
controls:9.75%
31
171
146
1596
18
70
159
1697
13
14
164
1753
—
7
9
169
1752
17
49
142
1643
20
142
104
1314
Physiotherapist
Z3226 [2001311560]
1.4e+00
1.3e+00
—
—
—
2.6e+00
2.6e+00
cases:9.04%
controls:2.49%
cases:3.39%
controls:0.91%
—
—
—
—
—
—
cases:4.40%
controls:0.35%
cases:9.68%
controls:0.76%
16
44
161
1723
6
16
171
1751
—
—
—
7
6
152
1686
12
11
112
1445
Abdominal ultrasound examination
JN3AE [2001305555]
1.7e+00
2.7e+00
—
—
—
—
2.1e+00
cases:8.47%
controls:1.64%
cases:5.65%
controls:0.40%
—
—
—
—
—
—
—
—
cases:8.06%
controls:1.03%
15
29
162
1738
10
7
167
1760
—
—
—
—
10
15
114
1441
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.8e+00
2.8e+00
—
—
—
2.2e+00
1.9e+00
cases:5.08%
controls:0.85%
cases:5.08%
controls:0.34%
—
—
—
—
—
—
cases:3.14%
controls:0.35%
cases:8.06%
controls:1.24%
9
15
168
1752
9
6
168
1761
—
—
—
5
6
154
1686
10
18
114
1438
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
8.4e-01
1.2e+00
1.9e+00
—
3.2e+00
1.2e+00
8.0e-01
cases:15.82%
controls:7.47%
cases:9.60%
controls:3.06%
cases:3.39%
controls:0.51%
—
—
cases:7.95%
controls:0.34%
cases:9.43%
controls:2.96%
cases:16.94%
controls:8.38%
28
132
149
1635
17
54
160
1713
6
9
171
1758
—
14
6
162
1755
15
50
144
1642
21
122
103
1334
Intravenous
ZX120 [2001311495]
2.1e+00
2.3e+00
—
—
—
—
2.0e+00
cases:6.78%
controls:0.91%
cases:3.39%
controls:0.34%
—
—
—
—
—
—
—
—
cases:5.65%
controls:0.82%
12
16
165
1751
6
6
171
1761
—
—
—
—
7
12
117
1444
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
1.9e+00
2.3e+00
—
—
1.0e+50
—
2.1e+00
cases:3.95%
controls:0.62%
cases:3.95%
controls:0.40%
—
—
—
—
cases:3.41%
controls:0.00%
—
—
cases:4.84%
controls:0.62%
7
11
170
1756
7
7
170
1760
—
—
6
0
170
1761
—
6
9
118
1447
Essential (primary) hypertension
I10 [45591453]
8.2e-01
1.0e+00
2.0e+00
—
2.3e+00
7.8e-01
9.9e-02
cases:27.12%
controls:14.04%
cases:18.08%
controls:7.30%
cases:9.04%
controls:1.36%
—
—
cases:13.07%
controls:1.53%
cases:15.72%
controls:7.86%
cases:18.55%
controls:17.10%
48
248
129
1519
32
129
145
1638
16
24
161
1743
—
23
27
153
1734
25
133
134
1559
23
249
101
1207
Case Management Agency
251B00000X [38004193]
2.4e-01
3.8e-01
9.2e-01
4.0e+00
1.1e+00
3.6e-01
-8.6e-02
cases:71.19%
controls:65.99%
cases:68.93%
controls:60.22%
cases:45.76%
controls:25.13%
cases:44.63%
controls:1.41%
cases:48.86%
controls:24.53%
cases:68.55%
controls:60.28%
cases:71.77%
controls:73.49%
126
1166
51
601
122
1064
55
703
81
444
96
1323
79
25
98
1742
86
432
90
1329
109
1020
50
672
89
1070
35
386
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.4e+00
2.2e+00
—
—
—
2.4e+00
1.2e+00
cases:8.47%
controls:2.26%
cases:4.52%
controls:0.51%
—
—
—
—
—
—
cases:3.77%
controls:0.35%
cases:5.65%
controls:1.72%
15
40
162
1727
8
9
169
1758
—
—
—
6
6
153
1686
7
25
117
1431
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
1.4e+00
1.7e+00
—
1.0e+50
1.0e+50
2.9e+00
9.5e-01
cases:8.47%
controls:2.21%
cases:4.52%
controls:0.85%
—
—
cases:3.39%
controls:0.00%
cases:5.11%
controls:0.00%
cases:6.92%
controls:0.41%
cases:4.84%
controls:1.92%
15
39
162
1728
8
15
169
1752
—
6
0
171
1767
9
0
167
1761
11
7
148
1685
6
28
118
1428
furosemide; oral, parenteral
C03CA01 [21601518]
1.3e+00
1.3e+00
1.8e+00
—
1.2e+00
1.6e+00
8.7e-01
cases:14.12%
controls:4.47%
cases:11.86%
controls:3.45%
cases:6.21%
controls:1.13%
—
—
cases:3.98%
controls:1.25%
cases:15.09%
controls:3.31%
cases:10.48%
controls:4.67%
25
79
152
1688
21
61
156
1706
11
20
166
1747
—
7
22
169
1739
24
56
135
1636
13
68
111
1388
Dentistry
C5 [903277]
4.9e-01
2.3e+00
—
—
—
1.9e+00
1.7e+00
cases:5.08%
controls:3.17%
cases:3.39%
controls:0.34%
—
—
—
—
—
—
cases:6.29%
controls:1.00%
cases:13.71%
controls:2.82%
9
56
168
1711
6
6
171
1761
—
—
—
10
17
149
1675
17
41
107
1415
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
1.1e+00
1.8e+00
—
1.0e+50
—
2.3e+00
1.8e+00
cases:3.95%
controls:1.41%
cases:5.08%
controls:0.85%
—
—
cases:3.95%
controls:0.00%
—
—
cases:5.66%
controls:0.59%
cases:9.68%
controls:1.79%
7
25
170
1742
9
15
168
1752
—
7
0
170
1767
—
9
10
150
1682
12
26
112
1430
Gas panel - Venous blood
24339-4 [3000991]
1.0e+00
1.9e+00
—
—
—
2.5e+00
1.5e+00
cases:4.52%
controls:1.70%
cases:5.65%
controls:0.91%
—
—
—
—
—
—
cases:5.66%
controls:0.47%
cases:8.87%
controls:2.13%
8
30
169
1737
10
16
167
1751
—
—
—
9
8
150
1684
11
31
113
1425
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.0e+00
1.9e+00
—
—
—
1.6e+00
1.3e+00
cases:10.17%
controls:3.96%
cases:7.34%
controls:1.13%
—
—
—
—
—
—
cases:5.66%
controls:1.18%
cases:13.71%
controls:4.26%
18
70
159
1697
13
20
164
1747
—
—
—
9
20
150
1672
17
62
107
1394
Medical Oncology
90 [38004507]
5.8e-01
1.2e+00
2.2e+00
1.0e+50
2.4e+00
7.9e-01
2.6e-01
cases:7.34%
controls:4.24%
cases:9.04%
controls:2.77%
cases:7.34%
controls:0.91%
cases:5.08%
controls:0.00%
cases:9.66%
controls:0.97%
cases:5.66%
controls:2.66%
cases:4.84%
controls:3.78%
13
75
164
1692
16
49
161
1718
13
16
164
1751
9
0
168
1767
17
17
159
1744
9
45
150
1647
6
55
118
1401
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
5.5e-01
1.6e+00
1.6e+00
1.0e+50
2.8e+00
1.4e+00
5.1e-01
cases:10.73%
controls:6.51%
cases:12.99%
controls:2.94%
cases:2.82%
controls:0.57%
cases:4.52%
controls:0.00%
cases:6.82%
controls:0.45%
cases:10.69%
controls:2.84%
cases:15.32%
controls:9.82%
19
115
158
1652
23
52
154
1715
5
10
172
1757
8
0
169
1767
12
8
164
1753
17
48
142
1644
19
143
105
1313
pH of Specimen
17433-4 [3019225]
9.1e-01
1.8e+00
—
1.0e+50
—
2.1e+00
1.8e+00
cases:4.52%
controls:1.87%
cases:5.08%
controls:0.85%
—
—
cases:4.52%
controls:0.00%
—
—
cases:5.66%
controls:0.71%
cases:8.06%
controls:1.44%
8
33
169
1734
9
15
168
1752
—
8
0
169
1767
—
9
12
150
1680
10
21
114
1435
zopiclone; oral
N05CF01 [21604654]
9.0e-01
1.4e+00
2.2e+00
—
9.9e-01
1.2e+00
9.2e-01
cases:14.69%
controls:6.56%
cases:12.99%
controls:3.68%
cases:4.52%
controls:0.51%
—
—
cases:2.84%
controls:1.08%
cases:12.58%
controls:4.02%
cases:12.90%
controls:5.56%
26
116
151
1651
23
65
154
1702
8
9
169
1758
—
5
19
171
1742
20
68
139
1624
16
81
108
1375
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.3e+00
2.0e+00
—
—
—
2.4e+00
1.3e+00
cases:9.60%
controls:2.83%
cases:6.78%
controls:0.96%
—
—
—
—
—
—
cases:10.06%
controls:1.00%
cases:8.06%
controls:2.40%
17
50
160
1717
12
17
165
1750
—
—
—
16
17
143
1675
10
35
114
1421
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
4.5e-01
9.7e-01
2.1e+00
—
1.7e+00
9.7e-01
3.6e-01
cases:29.94%
controls:21.45%
cases:23.73%
controls:10.53%
cases:9.04%
controls:1.25%
—
—
cases:9.09%
controls:1.82%
cases:23.90%
controls:10.64%
cases:35.48%
controls:27.75%
53
379
124
1388
42
186
135
1581
16
22
161
1745
—
16
32
160
1729
38
180
121
1512
44
404
80
1052
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.2e+00
2.2e+00
—
—
—
2.2e+00
1.2e+00
cases:7.34%
controls:2.26%
cases:4.52%
controls:0.51%
—
—
—
—
—
—
cases:4.40%
controls:0.53%
cases:4.84%
controls:1.58%
13
40
164
1727
8
9
169
1758
—
—
—
7
9
152
1683
6
23
118
1433
FEV1
20150-9 [3024653]
1.2e+00
2.2e+00
—
—
—
2.2e+00
1.2e+00
cases:7.34%
controls:2.26%
cases:4.52%
controls:0.51%
—
—
—
—
—
—
cases:4.40%
controls:0.53%
cases:4.84%
controls:1.58%
13
40
164
1727
8
9
169
1758
—
—
—
7
9
152
1683
6
23
118
1433
FEV1/FVC
19926-5 [3011505]
1.2e+00
2.2e+00
—
—
—
2.2e+00
1.2e+00
cases:7.34%
controls:2.26%
cases:4.52%
controls:0.51%
—
—
—
—
—
—
cases:4.40%
controls:0.53%
cases:4.84%
controls:1.58%
13
40
164
1727
8
9
169
1758
—
—
—
7
9
152
1683
6
23
118
1433
pantoprazole; oral, parenteral
A02BC02 [21600097]
9.4e-01
1.1e+00
1.3e+00
—
1.3e+00
1.3e+00
8.6e-01
cases:33.90%
controls:16.64%
cases:23.16%
controls:8.77%
cases:6.21%
controls:1.81%
—
—
cases:7.95%
controls:2.21%
cases:25.79%
controls:8.87%
cases:31.45%
controls:16.28%
60
294
117
1473
41
155
136
1612
11
32
166
1735
—
14
39
162
1722
41
150
118
1542
39
237
85
1219
Supplier / Service Provider
OMOP5117446 [33004]
-5.8e-01
-1.6e-01
—
—
—
3.0e+00
2.5e+00
cases:18.64%
controls:28.98%
cases:7.91%
controls:9.17%
—
—
—
—
—
—
cases:10.06%
controls:0.53%
cases:16.13%
controls:1.58%
33
512
144
1255
14
162
163
1605
—
—
—
16
9
143
1683
20
23
104
1433
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.8e-01
8.3e-01
1.8e+00
—
1.9e+00
9.0e-01
3.6e-01
cases:34.46%
controls:28.35%
cases:28.25%
controls:14.71%
cases:9.60%
controls:1.70%
—
—
cases:13.07%
controls:2.10%
cases:30.19%
controls:14.89%
cases:44.35%
controls:35.71%
61
501
116
1266
50
260
127
1507
17
30
160
1737
—
23
37
153
1724
48
252
111
1440
55
520
69
936
temazepam; oral
N05CD07 [21604642]
1.5e+00
1.6e+00
—
—
—
2.1e+00
1.2e+00
cases:10.73%
controls:2.55%
cases:6.21%
controls:1.36%
—
—
—
—
—
—
cases:7.55%
controls:0.95%
cases:8.06%
controls:2.47%
19
45
158
1722
11
24
166
1743
—
—
—
12
16
147
1676
10
36
114
1420
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.3e+00
1.6e+00
—
—
—
1.9e+00
1.9e+00
cases:7.91%
controls:2.21%
cases:3.95%
controls:0.85%
—
—
—
—
—
—
cases:5.03%
controls:0.77%
cases:10.48%
controls:1.65%
14
39
163
1728
7
15
170
1752
—
—
—
8
13
151
1679
13
24
111
1432
Leukocytes [#/volume] in Urine
30405-5 [3018095]
8.1e-01
1.5e+00
1.3e+00
—
2.9e+00
9.3e-01
6.1e-01
cases:15.82%
controls:7.70%
cases:14.69%
controls:3.68%
cases:3.39%
controls:0.91%
—
—
cases:7.39%
controls:0.45%
cases:8.81%
controls:3.66%
cases:16.94%
controls:9.96%
28
136
149
1631
26
65
151
1702
6
16
171
1751
—
13
8
163
1753
14
62
145
1630
21
145
103
1311
tacrolimus; oral, parenteral
L04AD02 [21603925]
—
—
—
—
—
2.6e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.30%
cases:4.03%
controls:0.34%
—
—
—
—
—
6
5
153
1687
5
5
119
1451
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5.4e-01
1.4e+00
1.1e+00
1.0e+50
2.7e+00
9.9e-01
1.9e-01
cases:18.08%
controls:11.43%
cases:19.21%
controls:5.49%
cases:3.95%
controls:1.30%
cases:6.21%
controls:0.00%
cases:9.09%
controls:0.68%
cases:14.47%
controls:5.91%
cases:20.97%
controls:17.99%
32
202
145
1565
34
97
143
1670
7
23
170
1744
11
0
166
1767
16
12
160
1749
23
100
136
1592
26
262
98
1194
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
5.5e-01
1.3e+00
1.1e+00
1.0e+50
2.7e+00
1.1e+00
1.9e-01
cases:19.21%
controls:12.05%
cases:18.64%
controls:5.66%
cases:3.95%
controls:1.30%
cases:6.21%
controls:0.00%
cases:9.66%
controls:0.74%
cases:15.09%
controls:5.85%
cases:20.97%
controls:18.06%
34
213
143
1554
33
100
144
1667
7
23
170
1744
11
0
166
1767
17
13
159
1748
24
99
135
1593
26
263
98
1193
More than one and less than three hours
ZXE10 [2001311401]
1.1e+00
9.7e-01
—
—
—
2.4e+00
1.6e+00
cases:16.95%
controls:6.40%
cases:4.52%
controls:1.75%
—
—
—
—
—
—
cases:7.55%
controls:0.77%
cases:11.29%
controls:2.54%
30
113
147
1654
8
31
169
1736
—
—
—
12
13
147
1679
14
37
110
1419
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
7.8e-01
1.0e+00
2.3e+00
—
—
1.6e+00
1.0e+00
cases:9.04%
controls:4.36%
cases:4.52%
controls:1.64%
cases:4.52%
controls:0.45%
—
—
—
—
cases:6.29%
controls:1.30%
cases:12.90%
controls:4.95%
16
77
161
1690
8
29
169
1738
8
8
169
1759
—
—
10
22
149
1670
16
72
108
1384
Bacterial infection, unspecified
A49.9 [45590816]
1.3e+00
—
—
1.0e+50
—
2.6e+00
2.4e+00
cases:3.39%
controls:0.91%
—
—
—
—
cases:2.82%
controls:0.00%
—
—
cases:4.40%
controls:0.35%
cases:7.26%
controls:0.69%
6
16
171
1751
—
—
5
0
172
1767
—
7
6
152
1686
9
10
115
1446
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
5.1e-01
1.3e+00
1.1e+00
1.0e+50
2.6e+00
9.9e-01
2.3e-01
cases:18.08%
controls:11.71%
cases:18.64%
controls:5.83%
cases:3.95%
controls:1.30%
cases:6.21%
controls:0.00%
cases:9.09%
controls:0.74%
cases:14.47%
controls:5.91%
cases:21.77%
controls:18.06%
32
207
145
1560
33
103
144
1664
7
23
170
1744
11
0
166
1767
16
13
160
1748
23
100
136
1592
27
263
97
1193
Telehealth
OMOP5556618 [722455]
4.5e-01
8.9e-01
1.2e+00
—
2.1e+00
9.9e-01
8.6e-01
cases:35.59%
controls:26.09%
cases:19.77%
controls:9.17%
cases:3.39%
controls:1.08%
—
—
cases:6.82%
controls:0.85%
cases:16.35%
controls:6.80%
cases:30.65%
controls:15.80%
63
461
114
1306
35
162
142
1605
6
19
171
1748
—
12
15
164
1746
26
115
133
1577
38
230
86
1226
Pharmacy visit
OMOP4822462 [581458]
8.0e-01
1.3e+00
1.0e+00
6.6e-01
1.3e+00
1.2e+00
1.3e+00
cases:96.05%
controls:91.62%
cases:93.79%
controls:81.10%
cases:65.54%
controls:40.63%
cases:4.52%
controls:2.38%
cases:72.16%
controls:42.31%
cases:94.34%
controls:82.68%
cases:98.39%
controls:94.16%
170
1619
7
148
166
1433
11
334
116
718
61
1049
8
42
169
1725
127
745
49
1016
150
1399
9
293
122
1371
2
85
Base excess in Venous blood by calculation
1927-3 [3002032]
7.9e-01
1.4e+00
2.3e+00
1.0e+50
—
1.9e+00
1.4e+00
cases:5.08%
controls:2.38%
cases:5.65%
controls:1.41%
cases:2.82%
controls:0.28%
cases:3.95%
controls:0.00%
—
—
cases:6.29%
controls:0.95%
cases:11.29%
controls:3.09%
9
42
168
1725
10
25
167
1742
5
5
172
1762
7
0
170
1767
—
10
16
149
1676
14
45
110
1411
Malaise and fatigue
R53 [45553741]
1.3e+00
1.8e+00
—
1.0e+50
—
1.7e+00
1.0e+00
cases:7.34%
controls:2.09%
cases:3.95%
controls:0.68%
—
—
cases:3.95%
controls:0.00%
—
—
cases:5.03%
controls:1.00%
cases:8.87%
controls:3.43%
13
37
164
1730
7
12
170
1755
—
7
0
170
1767
—
8
17
151
1675
11
50
113
1406
allopurinol; oral, parenteral
M04AA01 [21604131]
1.0e+00
1.6e+00
—
—
—
1.5e+00
1.6e+00
cases:4.52%
controls:1.70%
cases:6.78%
controls:1.41%
—
—
—
—
—
—
cases:5.66%
controls:1.30%
cases:8.87%
controls:1.99%
8
30
169
1737
12
25
165
1742
—
—
—
9
22
150
1670
11
29
113
1427
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.1e+00
1.7e+00
—
—
—
1.9e+00
1.0e+00
cases:12.99%
controls:4.64%
cases:9.04%
controls:1.87%
—
—
—
—
—
—
cases:6.92%
controls:1.12%
cases:11.29%
controls:4.33%
23
82
154
1685
16
33
161
1734
—
—
—
11
19
148
1673
14
63
110
1393
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
1.6e+00
—
—
—
—
—
3.0e+00
cases:5.08%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:6.45%
controls:0.34%
9
18
168
1749
—
—
—
—
—
8
5
116
1451
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
1.3e+00
1.6e+00
—
—
—
1.9e+00
1.4e+00
cases:6.78%
controls:1.98%
cases:3.95%
controls:0.85%
—
—
—
—
—
—
cases:5.03%
controls:0.77%
cases:10.48%
controls:2.75%
12
35
165
1732
7
15
170
1752
—
—
—
8
13
151
1679
13
40
111
1416
loperamide oxide; oral
A07DA05 [21600648]
—
2.3e+00
—
—
—
2.3e+00
—
—
—
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:7.55%
controls:0.83%
—
—
—
7
7
170
1760
—
—
—
12
14
147
1678
—
loperamide; oral
A07DA03 [21600646]
—
2.3e+00
—
—
—
2.3e+00
—
—
—
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:7.55%
controls:0.83%
—
—
—
7
7
170
1760
—
—
—
12
14
147
1678
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
7.8e-01
1.6e+00
—
—
2.9e+00
1.0e+00
8.7e-01
cases:7.34%
controls:3.51%
cases:5.65%
controls:1.19%
—
—
—
—
cases:5.11%
controls:0.28%
cases:3.77%
controls:1.42%
cases:13.71%
controls:6.25%
13
62
164
1705
10
21
167
1746
—
—
9
5
167
1756
6
24
153
1668
17
91
107
1365
mirtazapine; oral
N06AX11 [21604740]
9.1e-01
1.1e+00
—
—
—
1.5e+00
1.0e+00
cases:14.12%
controls:6.23%
cases:9.60%
controls:3.34%
—
—
—
—
—
—
cases:13.84%
controls:3.43%
cases:15.32%
controls:6.25%
25
110
152
1657
17
59
160
1708
—
—
—
22
58
137
1634
19
91
105
1365
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
2.4e+00
—
—
1.0e+50
1.0e+50
—
2.1e+00
cases:7.34%
controls:0.74%
—
—
—
—
cases:6.78%
controls:0.00%
cases:3.98%
controls:0.00%
—
—
cases:4.84%
controls:0.62%
13
13
164
1754
—
—
12
0
165
1767
7
0
169
1761
—
6
9
118
1447
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
6.2e-01
1.5e+00
—
—
—
1.8e+00
1.1e+00
cases:7.91%
controls:4.41%
cases:6.78%
controls:1.53%
—
—
—
—
—
—
cases:4.40%
controls:0.77%
cases:10.48%
controls:3.64%
14
78
163
1689
12
27
165
1740
—
—
—
7
13
152
1679
13
53
111
1403
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
1.1e+00
1.9e+00
—
—
1.0e+50
2.6e+00
1.4e+00
cases:3.95%
controls:1.36%
cases:4.52%
controls:0.74%
—
—
—
—
cases:6.25%
controls:0.00%
cases:3.77%
controls:0.30%
cases:7.26%
controls:1.85%
7
24
170
1743
8
13
169
1754
—
—
11
0
165
1761
6
5
153
1687
9
27
115
1429
Osmolality of Urine
2695-5 [3026782]
1.2e+00
1.7e+00
—
—
—
1.5e+00
1.4e+00
cases:13.56%
controls:4.41%
cases:9.04%
controls:1.70%
—
—
—
—
—
—
cases:5.03%
controls:1.12%
cases:10.48%
controls:2.75%
24
78
153
1689
16
30
161
1737
—
—
—
8
19
151
1673
13
40
111
1416
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
7.5e-01
1.4e+00
—
—
2.9e+00
9.9e-01
-2.4e-02
cases:12.99%
controls:6.56%
cases:10.73%
controls:2.83%
—
—
—
—
cases:5.11%
controls:0.28%
cases:6.29%
controls:2.42%
cases:8.06%
controls:8.24%
23
116
154
1651
19
50
158
1717
—
—
9
5
167
1756
10
41
149
1651
10
120
114
1336
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
2.0e+00
—
—
—
1.0e+50
—
2.3e+00
cases:3.39%
controls:0.45%
—
—
—
—
—
—
cases:3.41%
controls:0.00%
—
—
cases:4.03%
controls:0.41%
6
8
171
1759
—
—
—
6
0
170
1761
—
5
6
119
1450
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.1e+00
1.6e+00
—
—
—
2.2e+00
2.2e+00
cases:5.08%
controls:1.70%
cases:2.82%
controls:0.57%
—
—
—
—
—
—
cases:4.40%
controls:0.53%
cases:8.87%
controls:1.10%
9
30
168
1737
5
10
172
1757
—
—
—
7
9
152
1683
11
16
113
1440
Extensive abdominal CT
JN3BD [2001305556]
1.8e+00
—
—
—
—
—
2.5e+00
cases:3.95%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:4.84%
controls:0.41%
7
12
170
1755
—
—
—
—
—
6
6
118
1450
Physiotherapy
R4110 [2001310233]
8.4e-01
1.2e+00
2.8e+00
1.0e+50
—
1.3e+00
1.5e+00
cases:10.73%
controls:4.92%
cases:5.65%
controls:1.81%
cases:5.08%
controls:0.34%
cases:5.08%
controls:0.00%
—
—
cases:6.29%
controls:1.83%
cases:14.52%
controls:3.50%
19
87
158
1680
10
32
167
1735
9
6
168
1761
9
0
168
1767
—
10
31
149
1661
18
51
106
1405
denosumab; parenteral
M05BX04 [21604169]
2.1e+00
2.2e+00
—
—
—
1.5e+00
1.3e+00
cases:5.08%
controls:0.68%
cases:7.91%
controls:0.91%
—
—
—
—
—
—
cases:4.40%
controls:1.06%
cases:4.03%
controls:1.17%
9
12
168
1755
14
16
163
1751
—
—
—
7
18
152
1674
5
17
119
1439
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
2.1e-01
4.9e-01
2.0e+00
—
2.3e+00
7.0e-01
8.4e-02
cases:12.43%
controls:10.36%
cases:10.73%
controls:6.85%
cases:5.65%
controls:0.79%
—
—
cases:6.25%
controls:0.68%
cases:12.58%
controls:6.68%
cases:18.55%
controls:17.31%
22
183
155
1584
19
121
158
1646
10
14
167
1753
—
11
12
165
1749
20
113
139
1579
23
252
101
1204
prednisolone
A07EA01 [21600653]
1.2e+00
9.7e-01
1.4e+00
—
—
1.2e+00
8.5e-01
cases:23.73%
controls:8.43%
cases:10.17%
controls:4.13%
cases:2.82%
controls:0.68%
—
—
—
—
cases:11.95%
controls:3.78%
cases:18.55%
controls:8.86%
42
149
135
1618
18
73
159
1694
5
12
172
1755
—
—
19
64
140
1628
23
129
101
1327
prednisolone; oral, parenteral
H02AB06 [21602734]
1.2e+00
9.7e-01
1.4e+00
—
—
1.2e+00
8.5e-01
cases:23.16%
controls:8.38%
cases:10.17%
controls:4.13%
cases:2.82%
controls:0.68%
—
—
—
—
cases:11.95%
controls:3.78%
cases:18.55%
controls:8.86%
41
148
136
1619
18
73
159
1694
5
12
172
1755
—
—
19
64
140
1628
23
129
101
1327
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
5.2e-01
1.3e+00
1.4e+00
1.0e+50
2.9e+00
9.5e-01
2.7e-02
cases:15.82%
controls:10.02%
cases:14.12%
controls:4.36%
cases:3.39%
controls:0.85%
cases:4.52%
controls:0.00%
cases:7.95%
controls:0.45%
cases:10.06%
controls:4.14%
cases:13.71%
controls:13.39%
28
177
149
1590
25
77
152
1690
6
15
171
1752
8
0
169
1767
14
8
162
1753
16
70
143
1622
17
195
107
1261
Supine thorax X-ray examination
GD1QA [2001303648]
1.8e+00
2.3e+00
—
1.0e+50
—
1.6e+00
1.3e+00
cases:6.78%
controls:1.25%
cases:4.52%
controls:0.45%
—
—
cases:4.52%
controls:0.00%
—
—
cases:3.14%
controls:0.65%
cases:7.26%
controls:2.13%
12
22
165
1745
8
8
169
1759
—
8
0
169
1767
—
5
11
154
1681
9
31
115
1425
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
1.8e+00
—
—
—
—
2.3e+00
1.2e+00
cases:5.65%
controls:1.02%
—
—
—
—
—
—
—
—
cases:5.66%
controls:0.59%
cases:4.03%
controls:1.24%
10
18
167
1749
—
—
—
—
9
10
150
1682
5
18
119
1438
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
1.8e+00
—
—
—
—
2.3e+00
1.5e+00
cases:5.65%
controls:1.02%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.47%
cases:4.03%
controls:0.89%
10
18
167
1749
—
—
—
—
7
8
152
1684
5
13
119
1443
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.4e+00
1.7e+00
—
1.0e+50
—
2.4e+00
1.6e+00
cases:3.95%
controls:0.96%
cases:3.39%
controls:0.62%
—
—
cases:2.82%
controls:0.00%
—
—
cases:4.40%
controls:0.41%
cases:8.06%
controls:1.72%
7
17
170
1750
6
11
171
1756
—
5
0
172
1767
—
7
7
152
1685
10
25
114
1431
pH of Capillary blood
2745-8 [3009343]
1.8e+00
—
—
—
—
2.2e+00
1.4e+00
cases:5.65%
controls:1.02%
—
—
—
—
—
—
—
—
cases:5.03%
controls:0.59%
cases:4.84%
controls:1.24%
10
18
167
1749
—
—
—
—
8
10
151
1682
6
18
118
1438
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.2e+00
1.6e+00
—
—
—
1.1e+00
1.1e+00
cases:16.38%
controls:5.55%
cases:9.60%
controls:2.09%
—
—
—
—
—
—
cases:7.55%
controls:2.66%
cases:15.32%
controls:5.49%
29
98
148
1669
17
37
160
1730
—
—
—
12
45
147
1647
19
80
105
1376
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
1.5e+00
—
—
—
—
2.0e+00
1.9e+00
cases:2.82%
controls:0.62%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.59%
cases:6.45%
controls:1.03%
5
11
172
1756
—
—
—
—
7
10
152
1682
8
15
116
1441
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.2e+00
1.9e+00
—
1.0e+50
—
1.5e+00
2.0e+00
cases:5.08%
controls:1.58%
cases:5.08%
controls:0.79%
—
—
cases:2.82%
controls:0.00%
—
—
cases:3.14%
controls:0.71%
cases:12.90%
controls:1.99%
9
28
168
1739
9
14
168
1753
—
5
0
172
1767
—
5
12
154
1680
16
29
108
1427
Hypothyroidism, unspecified
E03.9 [45537945]
1.1e+00
2.0e+00
—
1.0e+50
—
1.9e+00
1.4e+00
cases:4.52%
controls:1.53%
cases:5.08%
controls:0.74%
—
—
cases:2.82%
controls:0.00%
—
—
cases:6.29%
controls:1.00%
cases:7.26%
controls:1.92%
8
27
169
1740
9
13
168
1754
—
5
0
172
1767
—
10
17
149
1675
9
28
115
1428
Office Visit
OMOP4822458 [581477]
8.4e-01
1.0e+00
—
—
2.0e+00
1.7e+00
1.4e+00
cases:15.25%
controls:7.24%
cases:6.21%
controls:2.38%
—
—
—
—
cases:2.84%
controls:0.40%
cases:7.55%
controls:1.54%
cases:18.55%
controls:5.49%
27
128
150
1639
11
42
166
1725
—
—
5
7
171
1754
12
26
147
1666
23
80
101
1376
Gas panel - Capillary blood
24337-8 [3022313]
1.9e+00
—
—
—
—
2.0e+00
—
cases:4.52%
controls:0.74%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.53%
—
—
8
13
169
1754
—
—
—
—
6
9
153
1683
—
12 lead EKG panel
34534-8 [3044889]
4.8e-01
6.2e-01
1.6e+00
1.0e+50
2.2e+00
4.6e-01
3.0e-01
cases:28.81%
controls:20.09%
cases:18.08%
controls:10.58%
cases:5.08%
controls:1.08%
cases:2.82%
controls:0.00%
cases:10.80%
controls:1.36%
cases:13.84%
controls:9.22%
cases:28.23%
controls:22.60%
51
355
126
1412
32
187
145
1580
9
19
168
1748
5
0
172
1767
19
24
157
1737
22
156
137
1536
35
329
89
1127
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.2e+00
2.0e+00
—
—
—
1.8e+00
1.4e+00
cases:4.52%
controls:1.41%
cases:6.21%
controls:0.91%
—
—
—
—
—
—
cases:4.40%
controls:0.77%
cases:7.26%
controls:1.92%
8
25
169
1742
11
16
166
1751
—
—
—
7
13
152
1679
9
28
115
1428
hydroxocobalamin
V03AB33 [21605256]
1.9e+00
1.9e+00
—
—
—
1.5e+00
—
cases:6.21%
controls:1.02%
cases:5.65%
controls:0.91%
—
—
—
—
—
—
cases:3.77%
controls:0.83%
—
—
11
18
166
1749
10
16
167
1751
—
—
—
6
14
153
1678
—
hydroxocobalamin; parenteral
B03BA03 [21601123]
1.9e+00
1.9e+00
—
—
—
1.5e+00
—
cases:6.21%
controls:1.02%
cases:5.65%
controls:0.91%
—
—
—
—
—
—
cases:3.77%
controls:0.83%
—
—
11
18
166
1749
10
16
167
1751
—
—
—
6
14
153
1678
—
Coloscopy
UJF32 [2001305029]
5.7e-01
2.0e+00
—
—
—
1.7e+00
3.6e-01
cases:6.21%
controls:3.62%
cases:3.95%
controls:0.57%
—
—
—
—
—
—
cases:5.03%
controls:0.95%
cases:4.84%
controls:3.43%
11
64
166
1703
7
10
170
1757
—
—
—
8
16
151
1676
6
50
118
1406
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
7.9e-01
1.3e+00
—
1.0e+50
—
2.3e+00
1.4e+00
cases:4.52%
controls:2.09%
cases:3.95%
controls:1.08%
—
—
cases:3.39%
controls:0.00%
—
—
cases:6.92%
controls:0.77%
cases:10.48%
controls:2.75%
8
37
169
1730
7
19
170
1748
—
6
0
171
1767
—
11
13
148
1679
13
40
111
1416
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.9e-01
6.6e-01
1.2e+00
—
9.1e-01
1.2e+00
5.2e-01
cases:46.33%
controls:32.26%
cases:27.12%
controls:16.19%
cases:9.04%
controls:2.83%
—
—
cases:7.95%
controls:3.35%
cases:38.36%
controls:16.31%
cases:48.39%
controls:35.78%
82
570
95
1197
48
286
129
1481
16
50
161
1717
—
14
59
162
1702
61
276
98
1416
60
521
64
935
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
1.0e+00
1.9e+00
—
—
—
1.8e+00
1.7e+00
cases:6.21%
controls:2.32%
cases:5.08%
controls:0.79%
—
—
—
—
—
—
cases:3.77%
controls:0.65%
cases:9.68%
controls:1.92%
11
41
166
1726
9
14
168
1753
—
—
—
6
11
153
1681
12
28
112
1428
FVC percent change Respiratory system
69982-7 [42868471]
1.3e+00
2.3e+00
—
—
—
1.9e+00
1.2e+00
cases:7.34%
controls:2.21%
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:3.14%
controls:0.47%
cases:4.84%
controls:1.44%
13
39
164
1728
7
7
170
1760
—
—
—
5
8
154
1684
6
21
118
1435
FEV1 --post bronchodilation
20155-8 [3023550]
1.3e+00
2.3e+00
—
—
—
1.9e+00
1.2e+00
cases:7.34%
controls:2.21%
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:3.14%
controls:0.47%
cases:4.84%
controls:1.44%
13
39
164
1728
7
7
170
1760
—
—
—
5
8
154
1684
6
21
118
1435
FEV1 percent change
69983-5 [42868472]
1.3e+00
2.3e+00
—
—
—
1.9e+00
1.2e+00
cases:7.34%
controls:2.21%
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:3.14%
controls:0.47%
cases:4.84%
controls:1.44%
13
39
164
1728
7
7
170
1760
—
—
—
5
8
154
1684
6
21
118
1435
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.3e+00
2.3e+00
—
—
—
1.9e+00
1.2e+00
cases:7.34%
controls:2.21%
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:3.14%
controls:0.47%
cases:4.84%
controls:1.44%
13
39
164
1728
7
7
170
1760
—
—
—
5
8
154
1684
6
21
118
1435
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.3e+00
2.3e+00
—
—
—
1.9e+00
1.2e+00
cases:7.34%
controls:2.21%
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:3.14%
controls:0.47%
cases:4.84%
controls:1.44%
13
39
164
1728
7
7
170
1760
—
—
—
5
8
154
1684
6
21
118
1435
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
9.1e-01
1.3e+00
—
1.0e+50
—
2.1e+00
1.4e+00
cases:4.52%
controls:1.87%
cases:3.95%
controls:1.13%
—
—
cases:2.82%
controls:0.00%
—
—
cases:5.66%
controls:0.71%
cases:10.48%
controls:2.75%
8
33
169
1734
7
20
170
1747
—
5
0
172
1767
—
9
12
150
1680
13
40
111
1416
Neurology
13 [38004458]
8.3e-01
6.3e-01
1.3e+00
1.0e+50
1.5e+00
1.5e+00
1.2e+00
cases:17.51%
controls:8.49%
cases:7.91%
controls:4.36%
cases:2.82%
controls:0.79%
cases:4.52%
controls:0.00%
cases:3.98%
controls:0.91%
cases:13.21%
controls:3.19%
cases:25.00%
controls:9.27%
31
150
146
1617
14
77
163
1690
5
14
172
1753
8
0
169
1767
7
16
169
1745
21
54
138
1638
31
135
93
1321
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
4.6e-02
1.2e+00
—
1.0e+50
2.3e+00
4.3e-01
1.3e-01
cases:5.08%
controls:4.87%
cases:7.34%
controls:2.43%
—
—
cases:2.82%
controls:0.00%
cases:3.98%
controls:0.40%
cases:4.40%
controls:2.90%
cases:9.68%
controls:8.59%
9
86
168
1681
13
43
164
1724
—
5
0
172
1767
7
7
169
1754
7
49
152
1643
12
125
112
1331
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.6e+00
1.7e+00
—
—
—
—
1.3e+00
cases:4.52%
controls:0.91%
cases:5.08%
controls:0.96%
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.85%
8
16
169
1751
9
17
168
1750
—
—
—
—
8
27
116
1429
Treatment plan or consultation
WZC00 [2001310885]
6.9e-01
1.1e+00
2.3e+00
—
—
1.1e+00
1.0e+00
cases:12.99%
controls:6.96%
cases:6.78%
controls:2.43%
cases:3.39%
controls:0.34%
—
—
—
—
cases:6.92%
controls:2.48%
cases:14.52%
controls:5.84%
23
123
154
1644
12
43
165
1724
6
6
171
1761
—
—
11
42
148
1650
18
85
106
1371
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
1.5e+00
—
—
—
—
—
3.3e+00
cases:3.95%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:8.87%
controls:0.34%
7
16
170
1751
—
—
—
—
—
11
5
113
1451
One hour or less
ZXE00 [2001311394]
6.8e-01
1.3e+00
—
—
—
1.7e+00
1.7e+00
cases:12.43%
controls:6.68%
cases:5.65%
controls:1.53%
—
—
—
—
—
—
cases:5.03%
controls:1.00%
cases:12.90%
controls:2.68%
22
118
155
1649
10
27
167
1740
—
—
—
8
17
151
1675
16
39
108
1417
calcium carbonate; oral
A12AA04 [21600863]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.06%
controls:0.34%
—
—
—
—
—
—
10
5
114
1451
calcium carbonate
A02AC01 [21600065]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.06%
controls:0.34%
—
—
—
—
—
—
10
5
114
1451
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
6.9e-01
1.7e+00
—
—
—
1.5e+00
8.6e-01
cases:6.78%
controls:3.51%
cases:7.91%
controls:1.53%
—
—
—
—
—
—
cases:6.29%
controls:1.48%
cases:10.48%
controls:4.74%
12
62
165
1705
14
27
163
1740
—
—
—
10
25
149
1667
13
69
111
1387
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
7.9e-01
1.4e+00
—
—
—
1.8e+00
2.2e-01
cases:7.91%
controls:3.74%
cases:5.65%
controls:1.47%
—
—
—
—
—
—
cases:8.18%
controls:1.48%
cases:5.65%
controls:4.60%
14
66
163
1701
10
26
167
1741
—
—
—
13
25
146
1667
7
67
117
1389
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.3e+00
—
—
—
—
1.4e+00
1.8e+00
cases:9.04%
controls:2.55%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.83%
cases:11.29%
controls:2.06%
16
45
161
1722
—
—
—
—
5
14
154
1678
14
30
110
1426
Psychiatry
26 [38004469]
7.9e-01
1.1e+00
—
—
1.5e+00
2.0e+00
1.0e+00
cases:10.17%
controls:4.87%
cases:5.65%
controls:1.98%
—
—
—
—
cases:4.55%
controls:1.08%
cases:11.95%
controls:1.71%
cases:13.71%
controls:5.36%
18
86
159
1681
10
35
167
1732
—
—
8
19
168
1742
19
29
140
1663
17
78
107
1378
Scheduled procedure
ZXD10 [2001311387]
8.0e-01
1.4e+00
—
—
—
1.3e+00
1.6e+00
cases:12.43%
controls:6.00%
cases:5.65%
controls:1.41%
—
—
—
—
—
—
cases:3.77%
controls:1.06%
cases:12.10%
controls:2.68%
22
106
155
1661
10
25
167
1742
—
—
—
6
18
153
1674
15
39
109
1417
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.2e+00
2.9e+00
—
—
—
1.8e+00
6.9e-01
cases:6.21%
controls:1.87%
cases:7.34%
controls:0.45%
—
—
—
—
—
—
cases:3.14%
controls:0.53%
cases:4.03%
controls:2.06%
11
33
166
1734
13
8
164
1759
—
—
—
5
9
154
1683
5
30
119
1426
Rheumatology
66 [38004491]
6.3e-01
1.3e+00
2.1e+00
—
—
1.3e+00
1.5e+00
cases:6.78%
controls:3.74%
cases:7.34%
controls:2.09%
cases:2.82%
controls:0.34%
—
—
—
—
cases:6.29%
controls:1.77%
cases:12.10%
controls:2.88%
12
66
165
1701
13
37
164
1730
5
6
172
1761
—
—
10
30
149
1662
15
42
109
1414
General Surgery
2 [38004447]
6.3e-01
1.1e+00
1.3e+00
—
—
1.0e+00
7.7e-01
cases:24.29%
controls:14.54%
cases:9.60%
controls:3.28%
cases:2.82%
controls:0.79%
—
—
—
—
cases:10.69%
controls:4.14%
cases:20.97%
controls:10.92%
43
257
134
1510
17
58
160
1709
5
14
172
1753
—
—
17
70
142
1622
26
159
98
1297
cefalexin; oral
J01DB01 [21602870]
6.0e-01
7.4e-01
—
—
2.2e+00
7.7e-01
6.4e-01
cases:38.42%
controls:25.58%
cases:15.25%
controls:7.92%
—
—
—
—
cases:8.52%
controls:1.02%
cases:15.09%
controls:7.62%
cases:37.90%
controls:24.31%
68
452
109
1315
27
140
150
1627
—
—
15
18
161
1743
24
129
135
1563
47
354
77
1102
Other and unspecified abdominal pain
R10.4 [45568113]
1.1e+00
1.1e+00
—
—
—
1.7e+00
6.7e-01
cases:14.12%
controls:5.32%
cases:5.08%
controls:1.70%
—
—
—
—
—
—
cases:6.92%
controls:1.36%
cases:8.87%
controls:4.74%
25
94
152
1673
9
30
168
1737
—
—
—
11
23
148
1669
11
69
113
1387
EKG study
11524-6 [3013512]
7.6e-01
7.1e-01
—
—
2.8e+00
8.0e-01
7.7e-01
cases:13.56%
controls:6.85%
cases:7.34%
controls:3.74%
—
—
—
—
cases:5.11%
controls:0.34%
cases:8.18%
controls:3.84%
cases:19.35%
controls:10.03%
24
121
153
1646
13
66
164
1701
—
—
9
6
167
1755
13
65
146
1627
24
146
100
1310
Otolaryngology
4 [38004449]
8.0e-01
9.4e-01
—
—
—
9.7e-01
4.9e-01
cases:20.34%
controls:10.30%
cases:10.17%
controls:4.24%
—
—
—
—
—
—
cases:11.95%
controls:4.91%
cases:16.13%
controls:10.51%
36
182
141
1585
18
75
159
1692
—
—
—
19
83
140
1609
20
153
104
1303
Corticotropin [Mass/volume] in Plasma
2141-0 [3035637]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.84%
controls:0.34%
—
—
—
—
—
—
6
5
118
1451
Gas panel - Central venous blood
97535-9 [1616796]
2.7e+00
—
—
—
1.0e+50
—
—
cases:3.95%
controls:0.28%
—
—
—
—
—
—
cases:4.55%
controls:0.00%
—
—
—
—
7
5
170
1762
—
—
—
8
0
168
1761
—
—
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
1.4e+00
—
—
—
—
—
2.7e+00
cases:3.39%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:0.41%
6
15
171
1752
—
—
—
—
—
7
6
117
1450
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
1.1e+00
1.5e+00
—
—
—
—
1.2e+00
cases:10.17%
controls:3.57%
cases:5.08%
controls:1.13%
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.13%
18
63
159
1704
9
20
168
1747
—
—
—
—
8
31
116
1425
Bacteria [Presence] in Urine
87829-8 [36304419]
9.5e-01
1.7e+00
1.9e+00
—
—
9.6e-01
8.0e-01
cases:14.12%
controls:6.00%
cases:11.86%
controls:2.38%
cases:2.82%
controls:0.45%
—
—
—
—
cases:5.66%
controls:2.25%
cases:14.52%
controls:7.07%
25
106
152
1661
21
42
156
1725
5
8
172
1759
—
—
9
38
150
1654
18
103
106
1353
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
9.9e-01
1.6e+00
1.7e+00
—
—
1.2e+00
8.0e-01
cases:15.25%
controls:6.28%
cases:11.86%
controls:2.55%
cases:2.82%
controls:0.51%
—
—
—
—
cases:7.55%
controls:2.36%
cases:15.32%
controls:7.49%
27
111
150
1656
21
45
156
1722
5
9
172
1758
—
—
12
40
147
1652
19
109
105
1347
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.1e+00
1.5e+00
—
—
—
1.3e+00
3.5e-01
cases:10.73%
controls:3.85%
cases:7.34%
controls:1.70%
—
—
—
—
—
—
cases:5.66%
controls:1.60%
cases:5.65%
controls:4.05%
19
68
158
1699
13
30
164
1737
—
—
—
9
27
150
1665
7
59
117
1397
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:0.48%
0
6
177
1761
—
—
—
—
—
7
7
117
1449
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.84%
controls:0.41%
—
—
—
—
—
—
6
6
118
1450
Chronic alcohol abuse
P15 [2002000811]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.34%
—
—
—
—
—
—
5
5
119
1451
Tacrolimus [Mass/volume] in Blood
11253-2 [3026250]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.34%
—
—
—
—
—
—
5
5
119
1451
Limited function/disability NOS
A28 [2002000162]
—
1.1e+00
—
—
2.5e+00
1.3e+00
8.3e-01
—
—
cases:2.82%
controls:0.96%
—
—
—
—
cases:3.98%
controls:0.34%
cases:4.40%
controls:1.24%
cases:5.65%
controls:2.54%
—
5
17
172
1750
—
—
7
6
169
1755
7
21
152
1671
7
37
117
1419
Specific gravity of Urine by Refractometry
5810-7 [3019150]
2.0e-01
8.6e-01
—
1.0e+50
2.5e+00
8.5e-01
-3.6e-01
cases:7.34%
controls:6.11%
cases:6.21%
controls:2.72%
—
—
cases:2.82%
controls:0.00%
cases:3.98%
controls:0.34%
cases:6.29%
controls:2.78%
cases:6.45%
controls:9.00%
13
108
164
1659
11
48
166
1719
—
5
0
172
1767
7
6
169
1755
10
47
149
1645
8
131
116
1325
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
7.9e-01
2.5e+00
—
—
—
1.5e+00
1.1e+00
cases:5.08%
controls:2.38%
cases:3.95%
controls:0.34%
—
—
—
—
—
—
cases:3.14%
controls:0.71%
cases:4.84%
controls:1.65%
9
42
168
1725
7
6
170
1761
—
—
—
5
12
154
1680
6
24
118
1432
moxonidine; oral
C02AC05 [21600401]
2.5e+00
—
—
—
—
—
—
cases:3.95%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
170
1761
—
—
—
—
—
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
2.5e+00
—
—
—
—
—
—
cases:5.65%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
10
9
167
1758
—
—
—
—
—
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
6.3e-01
8.1e-01
—
—
—
1.2e+00
1.2e+00
cases:12.43%
controls:7.02%
cases:5.08%
controls:2.32%
—
—
—
—
—
—
cases:9.43%
controls:3.01%
cases:21.77%
controls:7.49%
22
124
155
1643
9
41
168
1726
—
—
—
15
51
144
1641
27
109
97
1347
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
3.7e-01
—
—
—
—
2.4e+00
1.3e+00
cases:3.39%
controls:2.38%
—
—
—
—
—
—
—
—
cases:6.29%
controls:0.59%
cases:4.84%
controls:1.30%
6
42
171
1725
—
—
—
—
10
10
149
1682
6
19
118
1437
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
9.1e-01
—
—
—
—
1.4e+00
1.5e+00
cases:11.30%
controls:4.87%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.95%
cases:15.32%
controls:3.91%
20
86
157
1681
—
—
—
—
6
16
153
1676
19
57
105
1399
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
—
—
—
—
2.4e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.35%
cases:5.65%
controls:1.51%
—
—
—
—
—
6
6
153
1686
7
22
117
1434
metoprolol; oral, parenteral
C07AB02 [21601684]
1.1e+00
1.3e+00
—
—
—
1.1e+00
8.2e-01
cases:10.17%
controls:3.62%
cases:9.04%
controls:2.66%
—
—
—
—
—
—
cases:7.55%
controls:2.60%
cases:6.45%
controls:2.95%
18
64
159
1703
16
47
161
1720
—
—
—
12
44
147
1648
8
43
116
1413
disulfiram; oral
N07BB01 [21604821]
2.4e+00
—
—
—
—
—
—
cases:6.21%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
11
11
166
1756
—
—
—
—
—
—
pH of Urine
2756-5 [3015736]
2.9e-01
9.2e-01
1.0e+00
1.0e+50
2.4e+00
8.8e-01
-3.1e-02
cases:12.43%
controls:9.56%
cases:10.17%
controls:4.30%
cases:2.82%
controls:1.02%
cases:3.39%
controls:0.00%
cases:5.68%
controls:0.57%
cases:10.06%
controls:4.43%
cases:13.71%
controls:14.08%
22
169
155
1598
18
76
159
1691
5
18
172
1749
6
0
171
1767
10
10
166
1751
16
75
143
1617
17
205
107
1251
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
1.0e+00
—
—
—
—
—
2.4e+00
cases:2.82%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:4.84%
controls:0.48%
5
18
172
1749
—
—
—
—
—
6
7
118
1449
pH of Blood
11558-4 [3010421]
2.3e+00
—
—
1.0e+50
—
1.0e+50
—
cases:3.39%
controls:0.34%
—
—
—
—
cases:2.82%
controls:0.00%
—
—
cases:4.40%
controls:0.00%
—
—
6
6
171
1761
—
—
5
0
172
1767
—
7
0
152
1692
—
Eye discharge
F03 [2002000401]
2.3e+00
—
—
—
—
—
1.6e+00
cases:3.39%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.82%
6
6
171
1761
—
—
—
—
—
5
12
119
1444
Gout, unspecified
M10.9 [45543454]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.41%
—
—
—
—
—
—
5
6
119
1450
Weakness/tiredness general
A04 [2002000145]
9.8e-01
—
—
—
—
2.3e+00
1.1e+00
cases:3.95%
controls:1.53%
—
—
—
—
—
—
—
—
cases:5.66%
controls:0.59%
cases:5.65%
controls:1.99%
7
27
170
1740
—
—
—
—
9
10
150
1682
7
29
117
1427
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
—
—
—
—
—
-1.0e+50
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:5.65%
controls:0.62%
—
—
—
—
—
0
5
159
1687
7
9
117
1447
Gout
M10 [45533711]
2.2e+00
—
—
—
—
—
—
cases:4.52%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
8
9
169
1758
—
—
—
—
—
—
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.84%
controls:0.55%
—
—
—
—
—
—
6
8
118
1448
Immunohistochemistry procedure
117617002 [4035726]
—
2.2e+00
—
—
—
—
1.7e+00
—
—
cases:3.95%
controls:0.45%
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.76%
—
7
8
170
1759
—
—
—
—
5
11
119
1445
oxycodone; oral, parenteral
N02AA05 [21604260]
1.5e+00
2.2e+00
—
—
—
1.6e+00
9.7e-01
cases:4.52%
controls:1.08%
cases:3.95%
controls:0.45%
—
—
—
—
—
—
cases:4.40%
controls:0.89%
cases:6.45%
controls:2.54%
8
19
169
1748
7
8
170
1759
—
—
—
7
15
152
1677
8
37
116
1419
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
2.2e+00
—
—
—
—
—
1.5e+00
cases:8.47%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.89%
15
18
162
1749
—
—
—
—
—
5
13
119
1443
folic acid
V04CX02 [715877]
1.3e+00
1.5e+00
—
—
1.9e+00
2.2e+00
1.1e+00
cases:3.39%
controls:0.91%
cases:3.39%
controls:0.79%
—
—
—
—
cases:2.84%
controls:0.45%
cases:8.81%
controls:1.06%
cases:6.45%
controls:2.27%
6
16
171
1751
6
14
171
1753
—
—
5
8
171
1753
14
18
145
1674
8
33
116
1423
folic acid; oral, parenteral
B03BB01 [21601129]
1.3e+00
1.5e+00
—
—
1.9e+00
2.2e+00
1.1e+00
cases:3.39%
controls:0.91%
cases:3.39%
controls:0.79%
—
—
—
—
cases:2.84%
controls:0.45%
cases:8.81%
controls:1.06%
cases:6.45%
controls:2.27%
6
16
171
1751
6
14
171
1753
—
—
5
8
171
1753
14
18
145
1674
8
33
116
1423
Implantation of vascular injection port
TPX10 [2001309608]
2.2e+00
—
—
—
—
—
—
cases:3.39%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
171
1760
—
—
—
—
—
—
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.26%
controls:0.89%
—
—
—
—
—
—
9
13
115
1443
Thrombin time
3243-3 [3036489]
—
—
—
—
—
-1.0e+50
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:5.65%
controls:0.69%
—
—
—
—
—
0
6
159
1686
7
10
117
1446
Nausea and vomiting
R11 [45539317]
2.1e+00
—
—
—
—
—
1.8e+00
cases:5.08%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.69%
9
11
168
1756
—
—
—
—
—
5
10
119
1446
pH of Arterial blood
2744-1 [3019977]
8.5e-01
2.1e+00
—
—
—
—
1.1e+00
cases:4.52%
controls:1.98%
cases:4.52%
controls:0.57%
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.27%
8
35
169
1732
8
10
169
1757
—
—
—
—
8
33
116
1423
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
8.5e-01
2.1e+00
—
—
—
—
1.1e+00
cases:4.52%
controls:1.98%
cases:4.52%
controls:0.57%
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.27%
8
35
169
1732
8
10
169
1757
—
—
—
—
8
33
116
1423
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
8.5e-01
2.1e+00
—
—
—
—
1.1e+00
cases:4.52%
controls:1.98%
cases:4.52%
controls:0.57%
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.27%
8
35
169
1732
8
10
169
1757
—
—
—
—
8
33
116
1423
sulfadiazine and trimethoprim
J01EE02 [21602962]
5.5e-01
—
—
—
—
2.1e+00
6.3e-01
cases:6.78%
controls:4.02%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.47%
cases:4.03%
controls:2.20%
12
71
165
1696
—
—
—
—
6
8
153
1684
5
32
119
1424
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.7e+00
—
—
—
—
2.1e+00
1.3e+00
cases:3.95%
controls:0.74%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.47%
cases:4.03%
controls:1.10%
7
13
170
1754
—
—
—
—
6
8
153
1684
5
16
119
1440
Nutritional therapy
R4190 [2001310243]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.84%
controls:0.62%
—
—
—
—
—
—
6
9
118
1447
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.0e+00
6.7e-01
-1.0e+50
—
—
8.7e-01
1.1e+00
cases:14.69%
controls:5.83%
cases:5.08%
controls:2.66%
cases:0.00%
controls:0.62%
—
—
—
—
cases:7.55%
controls:3.31%
cases:17.74%
controls:6.87%
26
103
151
1664
9
47
168
1720
0
11
177
1756
—
—
12
56
147
1636
22
100
102
1356
General Practice Dentistry
1223G0001X [38003675]
1.6e+00
—
—
—
—
—
2.1e+00
cases:3.39%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
cases:7.26%
controls:0.96%
6
13
171
1754
—
—
—
—
—
9
14
115
1442
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
1.4e+00
2.1e+00
—
—
—
—
—
cases:2.82%
controls:0.74%
cases:3.95%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
5
13
172
1754
7
9
170
1758
—
—
—
—
—
Laceration/cut
S18 [2002000983]
6.6e-01
1.6e-02
—
—
—
1.1e+00
9.6e-01
cases:13.56%
controls:7.53%
cases:3.39%
controls:3.34%
—
—
—
—
—
—
cases:8.18%
controls:2.84%
cases:21.77%
controls:9.62%
24
133
153
1634
6
59
171
1708
—
—
—
13
48
146
1644
27
140
97
1316
Low back pain
M54.5 [45553207]
1.1e+00
7.4e-01
—
—
—
—
9.5e-01
cases:14.69%
controls:5.32%
cases:3.95%
controls:1.92%
—
—
—
—
—
—
—
—
cases:14.52%
controls:6.18%
26
94
151
1673
7
34
170
1733
—
—
—
—
18
90
106
1366
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
2.0e+00
5.1e-01
—
—
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.59%
cases:4.84%
controls:2.95%
—
—
—
—
—
7
10
152
1682
6
43
118
1413
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.0e+00
1.3e+00
—
—
—
2.0e+00
1.1e+00
cases:6.78%
controls:2.55%
cases:3.95%
controls:1.08%
—
—
—
—
—
—
cases:4.40%
controls:0.59%
cases:8.06%
controls:2.82%
12
45
165
1722
7
19
170
1748
—
—
—
7
10
152
1682
10
41
114
1415
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
2.0e+00
—
—
—
—
—
—
cases:3.39%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
171
1759
—
—
—
—
—
—
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
2.0e+00
—
—
—
—
—
—
cases:3.39%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
171
1759
—
—
—
—
—
—
Fever, unspecified
R50.9 [45582716]
1.1e+00
2.0e+00
—
—
—
—
1.5e+00
cases:6.21%
controls:2.15%
cases:5.65%
controls:0.79%
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.51%
11
38
166
1729
10
14
167
1753
—
—
—
—
8
22
116
1434
Sedation and analgesia
WX002 [2001310758]
5.3e-01
—
—
—
—
—
2.0e+00
cases:5.65%
controls:3.40%
—
—
—
—
—
—
—
—
—
—
cases:8.87%
controls:1.30%
10
60
167
1707
—
—
—
—
—
11
19
113
1437
Cells panel - Urine sediment
58434-2 [40761535]
5.9e-01
—
—
—
—
2.0e+00
1.5e+00
cases:4.52%
controls:2.55%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.53%
cases:6.45%
controls:1.51%
8
45
169
1722
—
—
—
—
6
9
153
1683
8
22
116
1434
Base excess in Arterial blood by calculation
1925-7 [3003396]
8.8e-01
2.0e+00
—
—
—
—
1.1e+00
cases:4.52%
controls:1.92%
cases:3.95%
controls:0.57%
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.27%
8
34
169
1733
7
10
170
1757
—
—
—
—
8
33
116
1423
Dietary counselling and surveillance
Z71.3 [45552101]
2.0e+00
—
—
—
—
—
—
cases:3.95%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
7
10
170
1757
—
—
—
—
—
—
Pneumonia, unspecified
J18.9 [45601123]
1.1e+00
1.9e+00
—
—
—
—
6.8e-01
cases:6.78%
controls:2.26%
cases:4.52%
controls:0.68%
—
—
—
—
—
—
—
—
cases:6.45%
controls:3.37%
12
40
165
1727
8
12
169
1755
—
—
—
—
8
49
116
1407
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
8.0e-01
1.9e+00
—
—
—
1.4e+00
1.2e+00
cases:6.78%
controls:3.17%
cases:6.21%
controls:0.96%
—
—
—
—
—
—
cases:3.14%
controls:0.77%
cases:8.06%
controls:2.61%
12
56
165
1711
11
17
166
1750
—
—
—
5
13
154
1679
10
38
114
1418
Pulmonary Disease
29 [38004472]
8.7e-01
8.5e-01
—
—
1.2e+00
1.0e+00
6.1e-01
cases:16.95%
controls:7.87%
cases:9.04%
controls:4.07%
—
—
—
—
cases:2.84%
controls:0.91%
cases:10.06%
controls:3.78%
cases:13.71%
controls:7.97%
30
139
147
1628
16
72
161
1695
—
—
5
16
171
1745
16
64
143
1628
17
116
107
1340
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
7.8e-01
1.9e+00
—
—
2.1e+00
1.5e+00
—
cases:3.39%
controls:1.58%
cases:5.08%
controls:0.79%
—
—
—
—
cases:2.84%
controls:0.34%
cases:3.77%
controls:0.89%
—
—
6
28
171
1739
9
14
168
1753
—
—
5
6
171
1755
6
15
153
1677
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
6.7e-01
7.0e-01
4.8e-01
—
7.2e-01
8.5e-01
1.0e+00
cases:14.12%
controls:7.75%
cases:14.69%
controls:7.87%
cases:3.95%
controls:2.49%
—
—
cases:5.11%
controls:2.56%
cases:16.35%
controls:7.68%
cases:21.77%
controls:9.00%
25
137
152
1630
26
139
151
1628
7
44
170
1723
—
9
45
167
1716
26
130
133
1562
27
131
97
1325
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
4.7e-01
1.9e+00
—
—
—
1.7e+00
6.7e-01
cases:3.39%
controls:2.15%
cases:3.95%
controls:0.62%
—
—
—
—
—
—
cases:3.77%
controls:0.71%
cases:4.84%
controls:2.54%
6
38
171
1729
7
11
170
1756
—
—
—
6
12
153
1680
6
37
118
1419
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
1.9e+00
—
—
—
1.0e+50
—
—
cases:3.95%
controls:0.62%
—
—
—
—
—
—
cases:3.41%
controls:0.00%
—
—
—
—
7
11
170
1756
—
—
—
6
0
170
1761
—
—
Body CT examination
JN4AD [2001310897]
1.4e+00
1.9e+00
—
—
—
—
—
cases:2.82%
controls:0.68%
cases:3.95%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
5
12
172
1755
7
11
170
1756
—
—
—
—
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
8.6e-01
1.0e+00
—
—
1.2e+00
6.5e-01
7.9e-01
cases:14.69%
controls:6.79%
cases:9.04%
controls:3.51%
—
—
—
—
cases:2.84%
controls:0.85%
cases:6.92%
controls:3.72%
cases:12.90%
controls:6.32%
26
120
151
1647
16
62
161
1705
—
—
5
15
171
1746
11
63
148
1629
16
92
108
1364
General anesthesia, balanced
WX408 [2001310808]
7.8e-01
1.5e+00
—
—
—
1.9e+00
1.8e+00
cases:9.60%
controls:4.64%
cases:3.39%
controls:0.79%
—
—
—
—
—
—
cases:3.77%
controls:0.59%
cases:10.48%
controls:1.85%
17
82
160
1685
6
14
171
1753
—
—
—
6
10
153
1682
13
27
111
1429
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:0.96%
—
—
—
—
—
—
7
14
117
1442
Oncology Clinic/Center
261QX0200X [38004268]
4.4e-01
1.8e+00
—
—
—
—
2.1e-01
cases:7.91%
controls:5.26%
cases:7.34%
controls:1.30%
—
—
—
—
—
—
—
—
cases:4.03%
controls:3.30%
14
93
163
1674
13
23
164
1744
—
—
—
—
5
48
119
1408
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
—
1.1e+00
—
—
—
—
1.8e+00
—
—
cases:2.82%
controls:0.96%
—
—
—
—
—
—
—
—
cases:8.06%
controls:1.44%
—
5
17
172
1750
—
—
—
—
10
21
114
1435
alendronic acid; oral
M05BA04 [21604152]
1.8e+00
—
—
—
—
1.6e+00
—
cases:5.08%
controls:0.91%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.65%
—
—
9
16
168
1751
—
—
—
—
5
11
154
1681
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.2e+00
1.8e+00
—
—
—
1.5e+00
1.4e+00
cases:4.52%
controls:1.36%
cases:5.08%
controls:0.91%
—
—
—
—
—
—
cases:3.14%
controls:0.71%
cases:7.26%
controls:1.85%
8
24
169
1743
9
16
168
1751
—
—
—
5
12
154
1680
9
27
115
1429
Teaching
WZC30 [2001310891]
6.8e-01
1.3e+00
—
—
—
1.8e+00
1.7e+00
cases:3.95%
controls:2.04%
cases:3.39%
controls:0.96%
—
—
—
—
—
—
cases:3.14%
controls:0.53%
cases:10.48%
controls:2.06%
7
36
170
1731
6
17
171
1750
—
—
—
5
9
154
1683
13
30
111
1426
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.3e+00
1.7e+00
—
—
—
—
1.4e+00
cases:3.95%
controls:1.08%
cases:4.52%
controls:0.85%
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.65%
7
19
170
1748
8
15
169
1752
—
—
—
—
8
24
116
1432
epinephrine
S01EA01 [21603673]
1.6e+00
—
—
—
—
—
—
cases:4.52%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
169
1751
—
—
—
—
—
—
epinephrine; parenteral
C01CA24 [21600303]
1.6e+00
—
—
—
—
—
—
cases:4.52%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
169
1751
—
—
—
—
—
—
Hematology
82 [38004501]
1.6e+00
—
—
—
—
—
—
cases:4.52%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
169
1751
—
—
—
—
—
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
9.4e-01
1.4e+00
—
—
—
1.6e+00
1.6e+00
cases:3.95%
controls:1.58%
cases:3.95%
controls:0.96%
—
—
—
—
—
—
cases:3.14%
controls:0.65%
cases:8.87%
controls:1.85%
7
28
170
1739
7
17
170
1750
—
—
—
5
11
154
1681
11
27
113
1429
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
7.2e-01
1.6e+00
—
—
—
—
4.5e-01
cases:5.65%
controls:2.83%
cases:6.21%
controls:1.36%
—
—
—
—
—
—
—
—
cases:7.26%
controls:4.74%
10
50
167
1717
11
24
166
1743
—
—
—
—
9
69
115
1387
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
1.6e+00
—
—
—
1.0e+50
—
7.2e-01
cases:7.34%
controls:1.64%
—
—
—
—
—
—
cases:2.84%
controls:0.00%
—
—
cases:5.65%
controls:2.82%
13
29
164
1738
—
—
—
5
0
171
1761
—
7
41
117
1415
X-ray examination of the lungs in one projection
GD1PA [2001303645]
1.6e+00
1.2e+00
—
—
—
—
1.4e+00
cases:5.65%
controls:1.25%
cases:3.39%
controls:1.02%
—
—
—
—
—
—
—
—
cases:5.65%
controls:1.44%
10
22
167
1745
6
18
171
1749
—
—
—
—
7
21
117
1435
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
7.6e-01
1.5e+00
—
1.0e+50
—
9.2e-01
6.6e-01
cases:7.91%
controls:3.85%
cases:5.08%
controls:1.13%
—
—
cases:2.82%
controls:0.00%
—
—
cases:3.77%
controls:1.54%
cases:8.06%
controls:4.33%
14
68
163
1699
9
20
168
1747
—
5
0
172
1767
—
6
26
153
1666
10
63
114
1393
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
4.7e-01
1.4e+00
—
—
—
1.5e+00
9.0e-01
cases:4.52%
controls:2.89%
cases:3.95%
controls:1.02%
—
—
—
—
—
—
cases:6.29%
controls:1.42%
cases:7.26%
controls:3.09%
8
51
169
1716
7
18
170
1749
—
—
—
10
24
149
1668
9
45
115
1411
prednisone
A07EA03 [21600655]
1.5e+00
1.9e+00
—
—
—
—
—
cases:5.65%
controls:1.30%
cases:2.82%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
10
23
167
1744
5
8
172
1759
—
—
—
—
—
prednisone; oral
H02AB07 [21602735]
1.5e+00
1.9e+00
—
—
—
—
—
cases:5.65%
controls:1.30%
cases:2.82%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
10
23
167
1744
5
8
172
1759
—
—
—
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
2.6e-01
5.9e-01
8.6e-01
—
1.5e+00
3.5e-01
1.4e-01
cases:32.20%
controls:26.88%
cases:27.12%
controls:17.03%
cases:5.08%
controls:2.21%
—
—
cases:9.66%
controls:2.33%
cases:23.90%
controls:18.14%
cases:40.32%
controls:37.09%
57
475
120
1292
48
301
129
1466
9
39
168
1728
—
17
41
159
1720
38
307
121
1385
50
540
74
916
Operative extraction of tooth
EBA10 [2001301925]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.26%
controls:1.72%
—
—
—
—
—
—
9
25
115
1431
Fungus identified in Specimen by Culture
580-1 [3000494]
—
—
—
—
—
1.6e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.89%
cases:8.87%
controls:2.13%
—
—
—
—
—
7
15
152
1677
11
31
113
1425
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
2.1e-01
2.2e-01
7.1e-01
—
1.5e+00
3.8e-01
2.4e-01
cases:33.90%
controls:29.32%
cases:18.64%
controls:15.51%
cases:3.39%
controls:1.70%
—
—
cases:6.82%
controls:1.65%
cases:20.13%
controls:14.66%
cases:38.71%
controls:33.10%
60
518
117
1249
33
274
144
1493
6
30
171
1737
—
12
29
164
1732
32
248
127
1444
48
482
76
974
macrogol; oral
A06AD15 [21600575]
1.5e+00
—
—
—
—
2.2e+00
—
cases:5.65%
controls:1.36%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.35%
—
—
10
24
167
1743
—
—
—
—
5
6
154
1686
—
hydrocortisone; oral, parenteral
H02AB09 [21602737]
9.4e-01
1.1e+00
—
—
—
1.2e+00
1.5e+00
cases:4.52%
controls:1.81%
cases:2.82%
controls:0.96%
—
—
—
—
—
—
cases:3.77%
controls:1.12%
cases:8.87%
controls:2.20%
8
32
169
1735
5
17
172
1750
—
—
—
6
19
153
1673
11
32
113
1424

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
156
192
40.82
140.48
17.9
7.0
0.87
1.06
mmol/l
8.08
151
180
99
99
19.79
96.41
10.1
4.3
115.91
73.69
ng/l
2.31
89
86
170
777
12.29
36.50
27.8
7.7
1.21
1.21
mmol/l
0.11
154
677
128
453
6.59
36.14
17.9
4.0
7.40
7.40
ph
0.26
112
330
80
220
5.55
29.05
6.0
2.4
22.90
24.17
%
0.32
75
206
86
257
5.29
28.19
6.4
2.3
12.61
14.17
umol/l
1.07
80
241
81
233
5.32
27.73
6.5
2.3
2.14
2.34
g/l
1.85
75
217
127
531
5.20
27.05
5.0
3.1
2.34
2.36
mmol/l
0.82
122
486
105
403
4.59
24.36
6.9
4.4
—
—
—
0
0
64
175
5.01
22.76
11.4
7.9
7.38
7.38
ph
0.23
42
90
62
169
4.96
22.07
11.4
8.0
1.30
1.65
mmol/l
0.24
56
146
62
170
4.93
21.90
6.2
2.7
0.20
0.22
g/l
0.71
57
162
57
163
4.57
18.84
14.9
8.6
—
—
—
0
0
41
89
5.60
18.79
2.4
1.7
—
—
—
0
0
25
32
8.84
18.74
6.0
1.7
7.42
7.42
ph
0.03
25
32
96
403
3.79
18.44
4.0
2.5
3.16
2.95
mg/l
0.25
87
353
34
65
6.15
17.77
1.6
2.6
1.44
1.34
g/l
0.18
28
60
53
150
4.51
17.66
3.6
4.3
62.16
67.28
e9/l
0.51
39
117
28
22
14.71
16.80
9.6
1.8
10.49
4.95
pmol/l
2.20
28
22
114
572
3.48
15.93
10.8
8.3
—
—
—
0
0
15
0
+∞
15.85
1.5
0.0
—
—
—
0
0
90
396
3.42
15.48
5.1
3.1
357.68
342.13
umol/l
0.60
80
359
61
215
3.71
14.76
11.0
9.3
104.52
104.29
mmol/l
0.15
61
215
126
696
3.41
14.58
22.0
10.6
1.24
1.19
inr
0.50
112
567
73
292
3.44
14.48
4.0
2.8
2.47
2.45
mmol/l
0.43
65
259
24
40
6.72
14.24
1.7
1.4
207.24
272.02
ug/g
0.66
18
23
136
811
3.38
13.37
13.0
7.4
2.83
2.96
%
0.24
129
769
136
813
3.37
13.27
13.4
7.6
9.04
8.73
%
0.60
129
775
22
18
13.65
12.99
2.4
1.3
95.05
118.06
pmol/l
1.17
22
18
145
909
3.51
12.89
13.2
7.5
0.20
0.19
e9/l
0.14
130
801
142
881
3.42
12.81
13.2
7.3
0.04
0.04
e9/l
0.08
126
763
16
5
34.70
12.79
2.1
1.6
2001.87
1684.00
ml
—
16
5
135
815
3.27
12.72
12.4
7.4
58.22
56.36
%
1.03
128
787
137
836
3.29
12.63
13.2
7.4
25.12
28.55
%
2.92
129
801
134
811
3.21
12.46
13.2
7.5
0.64
0.68
%
0.41
127
765
23
42
6.09
12.45
3.3
3.4
56.54
178.80
mg/l
0.41
17
36
23
42
6.09
12.45
3.3
3.4
50.98
36.72
mg/l
0.59
17
37
150
973
3.57
12.33
19.4
11.3
4.07
3.93
e9/l
0.34
136
858
140
881
3.24
11.92
13.4
7.2
0.61
0.56
e9/l
1.90
124
763
89
439
2.93
11.88
4.6
2.5
—
—
—
0
0
141
896
3.22
11.70
13.4
7.3
1.74
1.84
e9/l
0.74
124
801
22
24
10.21
11.36
4.9
2.3
—
—
—
0
0
90
455
2.86
11.36
2.8
1.7
18.74
20.83
nmol/l
0.63
83
384
40
125
3.79
11.32
13.3
3.3
1.22
1.23
mmol/l
0.11
40
108
138
877
3.10
11.24
14.7
7.0
11.49
11.44
umol/l
0.02
131
832
97
522
2.75
10.69
3.6
2.5
—
—
—
0
0
95
507
2.75
10.63
4.3
2.3
58.59
68.60
u/l
0.51
89
468
20
39
5.61
10.08
3.5
3.1
1.06
1.96
ratio
—
10
22
19
20
10.42
10.03
4.5
1.5
4.76
4.92
kpa
0.32
19
20
19
20
10.42
10.03
4.5
1.5
9.32
8.35
kpa
0.62
19
20
50
194
3.14
10.02
9.8
4.1
7.77
8.95
umol/l
0.16
43
172
122
758
2.70
9.80
6.9
3.0
279.17
111.55
ug/l
1.81
115
710
56
235
2.96
9.76
3.2
2.9
29.63
29.35
s
0.16
56
229
86
461
2.58
9.23
6.5
3.1
0.46
0.34
e6/l
0.25
74
342
44
167
3.13
9.09
9.8
7.6
7.42
7.42
ph
0.02
26
89
97
556
2.52
8.96
4.9
3.1
7.17
8.09
mmol/l
1.16
87
475
77
398
2.57
8.84
2.2
1.5
2.96
2.45
g/l
1.13
48
240
53
228
2.84
8.74
2.9
2.1
—
—
—
0
0
93
533
2.46
8.47
7.0
3.2
134.50
44.54
e6/l
0.53
82
416
12
7
18.17
8.18
41.3
47.7
7.13
6.96
ug/l
—
12
7
52
229
2.75
8.15
2.0
1.6
1571.46
1205.72
nmol/l
0.58
41
177
19
29
7.16
8.12
3.4
3.7
—
—
—
0
0
39
148
3.06
8.00
5.8
5.0
1.03
0.82
%
0.34
19
48
111
704
2.39
7.87
3.5
1.9
95.25
99.61
pmol/l
0.48
78
365
117
762
2.39
7.77
3.8
2.8
—
—
estimate
—
0
0
41
164
2.91
7.65
10.3
7.7
0.51
0.60
mmol/l
0.06
36
143
100
612
2.34
7.63
8.1
3.9
99.53
73.71
e6/l
0.20
85
434
21
55
4.17
7.48
4.5
5.1
300.13
302.83
mg/l
0.01
15
29
77
427
2.35
7.32
1.5
1.4
0.50
1.74
u/ml
1.34
17
109
47
207
2.69
7.30
1.3
1.3
—
—
—
0
0
17
27
6.81
7.12
1.8
1.4
—
—
—
0
0
29
99
3.28
7.06
7.9
5.1
—
—
—
0
0
36
140
2.94
7.04
5.8
5.2
0.19
0.15
%
0.11
16
39
66
350
2.36
6.88
2.5
2.0
1.41
1.09
mg/l
0.39
44
271
27
91
3.29
6.70
8.4
8.3
1.97
1.42
%
0.62
27
91
12
12
10.58
6.63
3.8
2.5
92.08
127.19
ug/l
0.24
12
12
54
267
2.43
6.54
4.6
3.2
2.84
1.65
e6/l
0.37
31
137
17
42
4.35
6.51
5.5
3.0
1.45
2.29
index
0.39
11
28
40
172
2.68
6.46
2.5
1.6
—
—
—
0
0
63
338
2.29
6.32
2.3
2.1
—
—
—
0
0
115
786
2.17
6.26
23.9
11.9
0.00
0.00
e9/l
0.18
99
643
25
86
3.20
5.99
2.8
1.6
0.39
0.43
mg/l
0.09
15
35
25
87
3.16
5.88
1.8
1.2
—
—
—
0
0
52
269
2.28
5.61
1.8
1.8
527.09
443.16
pmol/l
0.72
45
234
18
52
3.72
5.61
1.7
1.5
101.80
143.89
au/ml
—
5
15
34
145
2.64
5.55
5.9
5.8
0.14
0.22
%
0.15
14
37
48
241
2.33
5.54
2.1
1.4
817.78
569.45
titre
—
9
55
22
74
3.23
5.46
2.1
1.5
—
—
—
0
0
18
53
3.65
5.46
2.1
1.4
214.46
221.07
u/ml
0.04
13
29
25
91
3.01
5.45
8.8
8.3
0.68
0.62
%
0.64
25
91
10
11
9.52
5.35
5.0
1.5
17.70
28.40
umol/l
—
10
11
122
884
2.06
5.32
6.3
3.2
41.41
0.00
estimate
0.49
34
187
42
203
2.37
5.27
2.6
1.6
—
—
—
0
0
121
878
2.04
5.21
6.3
3.2
0.00
0.00
estimate
-0.00
34
184
12
19
6.66
5.17
1.9
2.8
34.08
32.79
pg
0.42
12
19
143
1106
2.18
5.15
8.3
3.5
71.89
44.01
u/l
1.53
137
1046
81
513
2.01
5.11
14.6
6.5
—
—
—
0
0
100
683
1.98
5.07
5.2
3.0
6.46
6.18
ph
1.16
47
385
122
893
2.02
5.07
6.4
3.2
0.00
0.00
estimate
-0.00
34
183
33
145
2.54
5.06
5.7
4.8
0.79
0.64
%
0.16
14
44
50
272
2.14
4.70
2.5
1.7
—
—
—
0
0
15
36
4.43
4.63
2.7
17.6
60.71
63.18
%
0.14
15
36
86
572
1.92
4.59
6.1
3.1
25.85
30.34
ng/l
0.35
74
378
14
32
4.64
4.54
1.2
3.0
—
—
—
0
0
51
283
2.10
4.54
5.4
3.3
25.09
260.99
ng/l
2.14
38
204
39
196
2.25
4.44
1.9
1.5
—
—
—
0
0
21
79
2.86
4.32
4.2
1.9
0.00
9.30
estimate
—
7
27
15
46
3.45
4.29
1.5
1.5
—
—
—
0
0
12
26
4.85
4.13
5.5
2.7
5.90
4.22
e9/l
1.07
12
26
7
7
10.32
4.04
1.9
1.3
—
—
—
0
0
8
11
7.53
3.90
5.3
1.2
92.61
88.93
%
—
8
11
8
11
7.53
3.90
1.3
1.0
2.01
1.75
mmol/l
—
8
11
19
72
2.82
3.86
3.1
1.4
1.34
4.69
iu/ml
—
5
9
7
8
9.03
3.80
1.0
1.1
147.57
122.50
nmol/l
—
7
8
14
45
3.28
3.73
1.4
1.0
—
—
—
0
0
15
51
3.11
3.66
2.7
3.0
—
—
—
0
0
10
21
4.96
3.61
2.1
1.4
20.80
17.84
ng/l
—
10
21
6
6
10.27
3.52
1.0
1.3
—
—
—
0
0
6
6
10.27
3.52
1.0
1.0
—
—
—
0
0
10
23
4.53
3.36
1.0
1.1
—
—
—
0
0
23
104
2.38
3.31
3.0
2.5
4.29
7.28
ug/l
1.26
18
94
170
1492
2.32
3.29
7.8
4.9
1.81
1.91
mu/l
0.51
164
1378
41
238
1.92
3.15
2.8
2.6
139.55
96.64
ug/g
0.52
33
189
71
488
1.73
3.14
7.5
3.3
0.00
0.00
estimate
-0.00
29
177
72
498
1.72
3.11
4.6
3.2
79.58
46.56
mg/l
0.46
53
302
86
628
1.67
3.02
2.5
2.0
—
—
—
0
0
34
188
1.98
3.00
1.4
1.3
—
—
—
0
0
5
5
10.22
2.99
4.6
8.2
—
—
—
0
0
31
166
2.04
2.98
1.2
1.2
—
—
—
0
0
8
17
4.86
2.95
3.3
34.8
10.04
11.27
%
—
8
17
23
112
2.20
2.81
5.2
3.0
—
—
—
0
0
29
155
2.03
2.80
3.9
1.8
0.00
0.08
estimate
—
7
37
58
388
1.71
2.79
12.4
5.0
—
—
—
0
0
27
141
2.07
2.78
6.7
3.3
—
—
—
0
0
30
163
2.00
2.78
4.2
5.0
7.58
34.44
ug/l
0.49
25
128
6
10
6.15
2.72
1.0
1.1
265.83
294.70
mg/l
—
6
10
6
10
6.15
2.72
1.5
1.3
—
—
—
0
0
36
212
1.86
2.64
3.2
3.0
4.29
5.36
e9/l
0.44
28
189
12
44
2.84
2.60
5.9
2.8
66.25
57.43
%
1.25
12
44
11
37
3.09
2.53
1.2
2.8
8266.82
88.87
e6/l
0.58
11
31
8
21
3.93
2.49
1.3
1.1
—
—
—
0
0
25
133
2.01
2.45
1.8
1.5
—
—
—
0
0
70
507
1.60
2.43
6.2
3.6
20.61
7.76
mg/mmol
0.90
46
299
16
71
2.37
2.42
13.6
3.8
36.90
36.94
°c
0.21
16
71
5
8
6.38
2.38
4.2
1.0
2201.00
1048.50
u/ml
—
5
8
13
53
2.56
2.33
2.3
1.2
—
—
—
0
0
8
23
3.58
2.29
2.5
1.3
—
—
—
0
0
45
296
1.68
2.26
1.2
1.3
1.04
11.56
u/ml
2.27
17
115
16
76
2.21
2.09
1.1
1.1
—
—
—
0
0
5
10
5.10
2.08
1.0
1.0
—
—
—
0
0
6
15
4.09
2.05
1.3
4.1
—
—
—
0
0
181
1702
2.34
1.98
36.7
12.1
—
—
—
0
0
5
11
4.64
1.95
1.8
2.5
1010.80
567.64
mg
—
5
11
12
52
2.40
1.92
6.4
5.4
0.72
0.86
%
0.68
12
45
67
503
1.51
1.92
1.6
1.4
—
—
—
0
0
7
22
3.26
1.90
1.4
2.2
3.39
3.35
nmol/l
—
7
22
22
123
1.89
1.89
2.4
2.5
—
19.60
—
0
8
16
80
2.09
1.86
6.3
4.2
—
—
—
0
0
47
641
0.65
1.83
2.7
2.8
—
—
—
0
0
11
47
2.42
1.81
3.7
4.8
1.49
1.22
mmol/l
0.36
11
47
8
30
2.74
1.74
1.1
1.0
—
—
—
0
0
8
30
2.74
1.74
4.8
1.5
—
—
—
0
0
7
24
2.99
1.74
1.9
1.5
—
—
—
0
0
175
1630
1.93
1.68
43.2
14.1
26.54
23.03
mg/l
0.73
157
1292
65
498
1.46
1.65
5.1
2.6
0.00
0.01
estimate
0.50
27
151
5
14
3.64
1.62
1.0
1.0
—
—
—
0
0
5
14
3.64
1.62
1.2
1.1
—
—
—
0
0
8
32
2.56
1.61
1.1
1.1
—
—
—
0
0
16
86
1.94
1.55
8.7
6.8
24.40
24.82
mmol/l
0.17
16
81
5
15
3.39
1.53
3.0
2.4
0.32
0.57
e9/l
—
5
15
5
15
3.39
1.53
3.0
1.3
3.14
3.67
mg/l
—
5
15
24
149
1.70
1.50
2.0
1.4
—
—
—
0
0
5
16
3.18
1.44
1.2
1.1
—
—
—
0
0
82
671
1.39
1.41
6.3
3.0
0.00
0.01
estimate
0.50
31
159
6
23
2.66
1.38
1.0
1.3
11.65
20.85
ug/l
—
6
23
5
17
2.99
1.36
1.0
1.1
—
—
—
0
0
12
61
2.03
1.36
2.6
1.7
—
—
—
0
0
45
333
1.46
1.35
1.6
1.3
26.18
35.71
iu/ml
0.21
11
95
6
24
2.55
1.31
3.7
2.1
—
—
—
0
0
6
25
2.44
1.25
1.8
2.0
—
—
—
0
0
6
25
2.44
1.25
1.8
2.0
—
—
—
0
0
6
25
2.44
1.25
1.8
2.0
—
—
—
0
0
6
25
2.44
1.25
1.8
2.0
—
—
—
0
0
24
157
1.61
1.25
1.9
1.6
—
—
—
0
0
153
1405
1.46
1.24
48.0
18.0
14.29
13.55
%
6.10
153
1392
5
19
2.67
1.22
1.4
1.3
—
—
—
0
0
5
20
2.54
1.16
2.4
2.1
—
—
—
0
0
5
20
2.54
1.16
2.4
1.8
11.40
10.80
mmol/l
—
5
20
14
82
1.76
1.08
2.4
2.2
—
—
—
0
0
5
22
2.31
1.04
1.2
1.5
—
—
—
0
0
5
23
2.20
0.98
1.6
1.2
—
—
—
0
0
30
223
1.41
0.89
1.2
1.3
—
—
—
0
0
8
43
1.90
0.88
2.3
1.4
—
—
—
0
0
6
32
1.90
0.82
1.3
1.0
—
—
—
0
0
6
32
1.90
0.82
1.3
1.0
—
—
—
0
0
0
27
0.00
0.78
0.0
2.9
—
44.17
—
0
27
13
84
1.59
0.74
1.8
1.4
—
—
—
0
0
7
42
1.69
0.69
4.6
3.6
3.73
3.93
mmol/l
—
7
42
46
383
1.27
0.66
6.6
3.1
1.01
1.02
kg/l
2.10
32
239
13
88
1.51
0.62
1.8
1.3
—
—
—
0
0
13
90
1.48
0.57
1.8
1.3
—
—
—
0
0
13
90
1.48
0.57
1.8
1.3
—
—
—
0
0
13
91
1.46
0.54
1.8
1.3
—
—
—
0
0
22
172
1.32
0.51
2.3
1.9
—
—
—
0
0
10
69
1.47
0.45
1.3
1.3
—
—
—
0
0
160
1543
1.23
0.44
6.4
4.8
5.86
5.85
mmol/l
0.03
152
1430
17
216
0.77
0.43
1.6
1.6
—
—
—
0
0
14
110
1.29
0.32
1.3
1.3
—
—
—
0
0
183
1803
1.41
0.31
62.4
21.6
4.26
4.56
e12/l
7.60
183
1772
183
1803
1.41
0.31
62.4
21.7
7.14
6.50
e9/l
3.56
183
1771
183
1803
1.41
0.31
63.5
22.3
38.54
40.79
%
5.64
183
1790
183
1803
1.41
0.31
62.1
21.5
30.77
30.24
pg
3.10
183
1791
183
1803
1.41
0.31
63.1
21.8
128.86
136.85
g/l
6.87
183
1790
183
1802
1.42
0.31
62.2
21.6
92.37
90.66
fl
4.09
183
1790
183
1801
1.44
0.31
62.5
21.7
255.99
250.83
e9/l
0.43
183
1777
163
1593
1.16
0.26
6.0
4.6
1.45
1.47
mmol/l
0.30
153
1485
58
538
1.11
0.24
5.7
5.2
2.39
2.95
ug/l
0.30
51
482
163
1596
1.15
0.23
5.9
4.8
4.42
4.68
mmol/l
2.64
154
1499
0
11
0.00
0.21
0.0
1.6
—
1.17
—
0
11
0
12
0.00
0.21
0.0
1.6
—
104.42
—
0
12
0
12
0.00
0.21
0.0
1.6
—
3.89
—
0
12
153
1495
1.12
0.21
8.0
5.6
38.20
38.38
mmol/mol
0.07
148
1408
0
14
0.00
0.20
0.0
1.1
—
209.99
—
0
14
0
14
0.00
0.20
0.0
3.8
—
—
—
0
0
72
683
1.09
0.19
2.4
1.8
1.47
1.33
mmol/l
0.47
62
579
154
1516
1.08
0.13
5.2
4.0
1.32
1.26
mmol/l
0.52
146
1407
31
330
0.93
0.10
3.7
3.1
0.82
0.77
ug/l
0.17
19
217
5
47
1.07
0.09
2.8
1.2
0.80
0.92
g/l
—
5
47
6
55
1.09
0.09
1.5
1.4
—
233.33
—
0
27
9
88
1.02
0.07
1.1
1.1
—
—
—
0
0
163
1619
1.05
0.04
6.6
5.3
2.47
2.76
mmol/l
3.85
155
1508
15
147
1.02
0.00
5.7
1.8
6.25
6.06
ph
—
10
96
5
50
1.00
0.00
15.8
9.9
—
—
—
0
0
6
61
0.98
-0.00
1.2
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
59.28
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
11.6
—
8.99
—
0
7
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.03
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint E4_PHOS_MET and mortality.

Females

Parameter HR [95% CI] p-value
E4_PHOS_MET 4.82 [3.0, 7.74] < 0.001
Birth year 0.995 [0.99, 1.0] 0.274

During the follow-up period (1.1.1998 — 31.12.2019), 78 out of 333 females with E4_PHOS_MET died.

Males

Parameter HR [95% CI] p-value
E4_PHOS_MET 3.918 [2.62, 5.86] < 0.001
Birth year 0.991 [0.98, 1.0] 0.048

During the follow-up period (1.1.1998 — 31.12.2019), 99 out of 326 males with E4_PHOS_MET died.

Mortality risk

Mortality risk for people of age

years, who have E4_PHOS_MET.

N-year risk Females Males
1 0.415% 0.867%
5 2.335% 4.788%
10 6.908% 11.571%
15 13.29% 21.978%
20 22.891% 36.068%

Relationships between endpoints

↥

Index endpoint: E4_PHOS_MET – Disorders of phosphorus metabolism and phosphatases

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data